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 Abstract 
This paper describes two methods for utilizing cancer associated proteases for targeting 
cancer therapy to the tumor.  The first method is designing a drug delivery system based on 
liposomes that are sensitive to cancer associated proteases.  Upon contact with the protease, the 
liposome releases its contents.  The second method is designing a prodrug that is based on a 
porin isolated from Mycobacterium smegmatis.  The porin is modified with protease consensus 
sequences, inhibiting its toxicity.  Upon contact with the protease, the drug is activated. 
Protease sensitive liposomes were synthesized that were sensitive to urokinase 
plasminogen activator.  This was done by synthesizing a cholesterol-anchored, uPA consensus –
sequence-containing, acrylic acid block copolymer and using it to form a covalently bound 
polymer cage around the outside of a hypertonic liposome.  Liposomes were synthesized that had 
a diameter of 136 nm.  Upon addition of the polymer the diameter increased by 2.69 nm, 
indicating it had successfully embedded into the liposome membrane.  After crosslinking with 
either a short peptide containing a lysine (so that it is a diamine) or ethylenediamine, the 
diameter increased between 5.33 nm and 14.1 nm (depending on the type and amount of the 
crosslinked).  Fluorescence release assays showed that the polymer cage could add in excess of 
thirty atmospheres of osmotic pressure resistance, and, under isobaric conditions, would prevent 
release of much of the liposomal contents.  Upon treatment with uPA, the polymer caged 
liposomes released a significantly larger amount of their contents making the liposomes protease 
sensitive. 
MspA was shown to be a very stable protein able to be imaged by AFM.  AFM imaging 
demonstrated that MspA is able to form native pore structures in membranes making it a good 
imitator of the membrane attack complex.  MspA was demonstrated to be highly cytotoxic, but 
poor at distinguishing between cells.  Pro-MspA was synthesized by adding a hydrophilic 
peptide to MspA that prevents insertion. A uPA cleavage sequence embedded causes the MspA 
to become activated at the cancer site.  This was demonstrated in tests against uPA and non-uPA 
producing cell lines. 
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1. Targeting Cancer  
1.1. Current Cancer Therapy 
Cancer is actually a collection of similar diseases that are marked by an uncontrolled 
proliferation of certain cells.  Usually, this is caused by a series of genetic disruptions that 
prevent proper control of either cell division or apoptosis (Figure 1.1.1).  This leads to rapidly 
increasing cell populations that invade the rest of the body, disrupting normal functions and 
producing toxic byproducts.  Eventually, the disruption of normal functions and/or toxic 
byproducts grows to a point where the uncontrolled proliferation becomes lethal.   
 
 
Figure  1.1.1 Cancer is caused by a build up of mutations in a cell line.  Most healthy 
humans start with 0-1 mutations from the germ line.  Over time mutagens add more 
mutations to various cell lines.  Mutations that do not kill the cell, but provide a survival 
advantage can build up and cause cancer. 
 
Although much advancement has been made in cancer therapy in the last several decades, 
cancer is still a poorly controlled disease with unsatisfactory treatment options.  According to the 
NIH, nearly 1.5 million Americans will be newly diagnosed with cancer this year and over half a 
million will die from cancer, a mortality rate of almost 40%.1  Malignant cancer was the second 
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leading cause of death in the United States in 2005 (the last year statistics are available), led only 
by cardiovascular disease.2  The need for more effective treatment options is evident. 
Current cancer treatments are focused mainly on targeting rapidly dividing cells, the 
common symptom of almost all cancers.  The goal is that a short treatment with a drug that kills 
dividing cells will catch most of the cancer cells dividing, thus killing them, while only a small 
fraction of the body’s normal cells will be dividing, sparing them from the drug’s lethality 
(Figure 1.1.2).3  Unfortunately, although most of the body’s cells are dividing quite slowly, there  
 
 
Figure  1.1.2 Many cancer therapies target cancer by targeting rapidly dividing cells.  Since most 
cancers have a much higher percent of their population dividing at any given time versus healthy 
cells, a drug that kills dividing cells will select against cancer cells. 
 
are certain cell types which do naturally divide very rapidly, including blood cell 
precursors (red and white), cells lining the mouth and digestive track, hair follicles and 
reproductive cells.  These cells are also targeted by most current cancer chemotherapy 
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techniques, causing most of the well known cancer chemotherapy side effects – killing blood cell 
precursors leads to susceptibility to infection and lethargy, killing digestive track cells leads to 
upset stomach and diarrhea, killing the cells lining the mouth leads to loss of appetite and ability 
to taste, killing hair follicles leads to hair loss, and killing reproductive cells leads to sterility.4 
 
 
Figure  1.1.3 Although most healthy cells are not dividing rapidly, some subpopulations of 
healthy cells (e.g. blood precursors, follicles, etc.) do divide relatively rapidly.  Thus, 
standard cancer therapy also selects against these cells causing many of the well known side 
effects. 
 
Targeting cancer chemotherapy to the cancer cell better is a major goal of cancer therapy 
research today.  Many techniques are being used to do this including drug delivery systems 
(delivering the drug more specifically to the tumor site), antibody targeted treatment (using 
antibodies to direct the drug to an antigen upregulated at the tumor site), metabolism targeted 
treatment (tagging the treatment with metabolites that are needed by the cancer cell to trigger 
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uptake), and proteome targeted treatment (targeting the protein signature of the cancer cell – 
either over or under expression of various proteins).  
1.2. Cancer Markers – Differentiating Between Cells 
One of the biggest challenges in cancer therapy is that cancer is a disease of the body’s 
own cells.  Because of this, it is often very challenging to diagnose cancer until the disease is 
quite progressed.  This also affects treatment efficiency – since the cancer cells have the same 
enzymes, replication equipment, structural features, etc. as healthy cells, treatments that delineate 
cancer cells from healthy cells are hard to come by.  This is why (as mentioned above), cancer is 
usually treated based on the symptom, rapidly growing cells and/or leaky vessels, rather than 
specifically targeting the cancer.  Therefore, determining ways to distinguish cancerous cells 
from healthy cells is a large area of research in cancer therapy.   
Many tumor biomarkers have been determined to date, and have been used mostly to 
diagnose cancer, to determine the prognosis (how far advanced is the tumor, what chance is there 
of curing it), and to determine the effectiveness of the treatment methods.  Recently, though, cell 
surface antigens (proteins or protein fragments that are expressed on the outside of the cell 
membrane) that are cancer cell markers have been used to target antibody-drug conjugates to the 
tumor cells.   
Most classic cancer biomarkers are not useful for targeting treatment to the cancer cell.  
This is because most classic cancer biomarkers are soluble markers, used for blood or serum 
tests.  Also, classic biomarkers are usually proteins that are naturally occurring at a low level in 
the body (often proteins that are upregulated in the developing fetus and then downregulated in 
adulthood).  Because there is some level of the biomarker naturally in the body, high occurrences 
of false positives and false negatives occur, making them unsuitable for treatment.  One of the 
best cancer biomarkers known is prostate specific antigen (PSA).  Associated with prostate 
cancer, PSA is a serine protease that is found in low levels in healthy men.  Men with prostate 
tumors, either benign or malignant, show a large spike in blood concentration of PSA, making 
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PSA a very useful tool for early detection of prostate cancer.  Unfortunately, since PSA is not 
attached to the cancer cells in any way, it can’t be used for antibody targeted treatment.  Another 
biomarker that has been effective in cancer treatment is cancer antigen 125 (CA-125).  CA-125 is 
associated with ovarian cancer and, to a lesser degree, with breast cancer and is a cell surface 
protein that regulates adhesion of the cell.  Over 80% of ovarian cancer patients show elevated 
levels of CA-125 in the serum.  Although, CA-125 does not have the diagnostic power of PSA, 
due to the high range of values found in healthy women, the concentration of CA-125 can be 
used to develop a prognosis of the cancer, to determine the effectiveness of the treatment 
regimen, and to monitor for recurrence of the tumor after remission.  CA-125 cannot be used as 
an antibody target, even though it is a cell surface antigen, because of the high concentrations 
often found in healthy women indicating that healthy cells express the protein as well.  Other 
well known biomarkers include carcinoembryonic antigen (CEA), alpha-fetoprotein and human 
chorionic gonadotropin, although none of these has found a use in targeting treatments to the 
cancer cell, and are only useful for diagnosis or prognosis of the disease.5,6,7 
Antibody targeting of tumors has found some success in cancer therapy, although, not by 
specifically targeting the cancer cells, but simply the tissue that the cells come from.  The FDA 
has approved eight monoclonal antibody treatments for cancer:  Rituximab targets CD20 (a 
surface antigen on B cells, for treatment of Non Hodgkin’s Lymphoma), Trastuzumab targets 
HER2 (a metastatic breast cancer marker, for treatment of metastatic breast cancer), 
Alemtuzumab targets CD52 (a surface antigen on B and T cells, for treatment of Chronic 
Lymphocytic Leukemia), Bevacizumab targets VEGF (vascular endothelial growth factor, for 
treatment of metastatic colorectal carcinoma), Cetuximab targets EGFR (epidermal growth factor 
receptor, for treatment of metastatic colorectal caner), Tositumomab and Ibritumomab targets 
CD20 (a surface antigen on B cells, for treatment of Non Hodgkin’s Lymphoma), and 
Gemtuzumab ozogamicin targets CD33 (a monomyeloid hematopoetic progenitor cell marker, 
for treatment of acute myeloid leukemia).  All except the last three are pure antibody treatment, 
that is, the antibody is given alone and causes an immune reaction to the cancer cell.  The last 
 6 
three are antibody’s conjugated to either a radioisotope (Tositumomab, Ibritumomab) or an 
immunotoxin (Gemtuzumab ozogamicin).8  
Although, these antibody targeted treatments have been approved, they are not that 
effective for several reasons.  First, the monoclonal antibodies, themselves, are not very 
cytotoxic and rely upon the immune system to recognize them and kill the cancer cell.  
Unfortunately, this only happens in ~5-15% of cases, making these treatments not very 
favorable.  Also, the monoclonal antibodies are (by necessity) produced in non-humans (usually 
mice).  This causes the body to recognize the antibody as foreign, which can lead to either 
simply removal from the body (rendering it ineffective) or causing an allergic reaction (which 
can prove fatal).  Much work has been done on this, though, by making chimeric antibodies, 
where the FAB fragment is from a mouse but the FC fragment is human or various variations 
thereof.  Finally, the antibodies are not cancer specific antibodies, but tissue specific antibodies.  
This means, the antibody does not target the cancer specifically, it targets the tissue that the 
cancer came from.  Therefore, the antibody can also attack healthy non-cancerous tissue that 
comes from the same tissue as the cancer.8, 9 
Since the main drawback to monoclonal treatment is the lack of cytotoxicity, the obvious 
answer is to conjugate something cytotoxic to the antibodies.  This has been tried several times, 
but has yet to show excellent outcomes.  The best outcomes come from conjugating a 
radioisotope to the antibody (Tositumomab, Ibritumomab).  This is not that effective, though, 
because the amount of time the antibody spends in circulation before becoming trapped at the 
tumor site is quite long and allows a large portion of the radioisotope to break down before 
reaching the tumor, delivering unwanted radiation to the rest of the body and decreasing the dose 
of radiation that reaches the tumor.  Conjugating a toxin to the antibody has been tried as well 
(Gemtuzumab ozogamicin).  Again, since the antibody spends a lot of time in circulation before 
becoming trapped at the tumor site, the toxin can interact with many things, because the antibody 
does not prevent it from acting.  This can have drastic side effects, up to and including death, 
depending on how powerful the toxin is.  Finally, attaching chemotherapy drugs to the antibody 
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have failed miserably to this point, although attempts are still being made.  This is primarily due 
to immune responses against the conjugate.  Chemotherapy drugs are, for the most part, small 
molecules that should be highly immunoreactive, but are too small to be noticed by the immune 
system.  Once they are conjugated to an antibody, they become considerably larger and they are 
easily recognized by the immune system, often with violent results.8 
Although much more work can and is being done on antibody targeted treatments, they 
are not going to easily be the magic bullets in the fight against cancer.  Other methods for 
targeting treatments to the cancer cell need to be found. 
1.3. Proteases – Targeting the Proteome of the Cancer Cell 
Although most tumor biomarkers have failed to produce a reliable and effective antibody 
targeted treatment, one class of biomarkers has the potential for a different type of targeted 
treatments – proteases (Figure 1.3.1).  Proteases are a class of enzyme that catalyzes the cleavage 
of the peptide bond in other proteins.  They can be very specific (only being able to degrade one 
peptide bond in one protein) or extremely broad (being able to cleave the peptide bond every 
time there is a lysine).  Quite a few proteases are known to be necessary for cancer development 
and progression including Matrix Metalloproteinases (MMPs), Tissue Serine Proteases, and the  
 
 
Figure  1.3.1 Proteases known in the progression of cancer 
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Cathepsins.  Many of these proteases are either upregulated in cancer (that is they have a 
much higher activity in the tumor than in healthy tissue), are misexpressed (that is they are found 
in compartments where they should not be found), or are proteases that are involved in 
embryonic development, but are not found to any significant extent in an adult.10   
Matrix metalloproteinases are the classic cancer associated proteases (Figure 1.3.2).  
MMPs are a family of zinc proteases that are named for the zinc and calcium ions that are 
required as cofactors.  There are 21 different known MMPs that are grouped into families based 
on their substrates: collagenases, gelatinases, stromelysins, matrilysin, metalloelastase, 
enamelysin, and membrane-type MMPs.  As can be seen from the family names, MMPs degrade 
the proteins that make up the extracellular matrix (ECM) and the basement membrane (BM).  
Interestingly, MMPs are usually not produced by the cancerous cells themselves, but by the 
stromal cells surrounding the tumor.  This is because the cancerous cells give off a variety of cell  
 
 
Figure  1.3.2 MMP upregulation by the tumor and surrounding cells 
 
signals that cause the surrounding stromal cells to highly upregulate their production of 
MMPs.  MMPs are vital to cancer survival and progression for several reasons – they cleave cell 
surface bound growth factors from the stromal and epithelial cells and release them to interact 
with the cancer cells to stimulate growth, they play a role in angiogenesis by opening the ECM to 
new vessel development and by releasing pro-angiogenic factors and starting pro-angiogenic 
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protease cascades, and they play a major role in tumor metastasis by degrading the ECM and the 
BM allowing the cells to pass through and releasing ECM and BM fragments which stimulates 
cell movement.  MMPs are not perfectly specific, they usually cleave several related proteins, 
but consensus sequences (the sequence of amino acids that a protease targets) have been 
determined for several MMPs and are shown in table 1.3.1, allowing peptides to be created that 
are selectively cleaved by the target MMP.10, 11, 12, 13, 14, 15   
Several serine proteases have well-documented roles in cancer as well, especially 
urokinase plasminogen activator (uPA) and plasmin (Figure 1.3.3).  uPA has actually been used 
with excellent success as a prognostic marker for breast cancer.  uPA is a very specific protease 
that binds to its receptor, uPAR, and cleaves the inactive plasminogen to the active plasmin.  
This is the first step in a well known cascade that causes angiogenesis and uPA is associated with 
angiogenesis in tumors, although it is also very active in tumor metastasis.  Plasmin is a 
somewhat non-specific protease that goes on to cleave many things including activating 
procollagenases, degrading the ECM, and releasing/activating growth factors.  Although plasmin 
is somewhat non-specific and a consensus sequence is hard to determine, uPA does have a well 
defined consensus sequence shown in table 1.3.1.10, 11, 15, 16, 17 
 
 
Figure  1.3.3 Urokinase Plasminogen Activator and Cancer Progression 
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Cathepsins, with a few exceptions, are cysteine proteases.  Often found in the 
lysosomal/endosomal pathway, cathepsins usually operate at low pH values, but some are still 
active at neutral pH.  Three of the cathepsins (B, D, and L) that are active at neutral pH are often 
misexpressed in cancer, causing activation outside of the cells.  This activation outside of the cell 
can cause ECM degradation, initiate known ECM degradation cascades, cathepsin B is known to 
activate uPA, and cathepsin D is known to activate Insulin-like Growth Factors.  Consensus 
sequences have been found for cathepsins B, D and L and are shown in table 1.3.1.10, 11, 18, 19 
The proteases with known consensus sequences that are activated at the tumor site can be 
used to target therapy.  To date this has been primarily done with pro-drug activation through 
cleavage by one of the proteases.  In 2001, Liu et. al. demonstrated an anthrax toxin that was 
made sensitive to uPA by replacing the cleavage sequence for furin with the cleavage sequence 
for uPA.  This caused the anthrax toxin to only be activated by uPA producing cells.17  In 2003, 
Thor proposed a ricin toxin that could be activated by many of the proteases depending on the 
sequence inserted.  Ricin A-chain was connected to the B-chain through the protease consensus 
sequence.  Only at protease producing cells would the A-chain and B-chain be separated, 
activating the toxin.18  In 2007, Warnecke et. al. demonstrated a modified form of methotextrate 
that could be cleaved and activated by plasmin or cathepsin B.20  The initial success of targeting 
cancer treatment to the cancer cell through the proteases the cancer cell expresses invites more 
interest in this topic. 
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Table  1.3.1 Consensus Sequences of Several Well Characterized Cancer Associated Proteases 
MMP Consensus 
MMP-1 VPMS-MRGG 
MMP-2 IPVS-LRSG 
MMP-3 RPFS-MIMG 
MMP-7 VPLS-LTMG 
MMP-9 VPLS-LYSG 
MMP-11 HGPEGLRVGFYESDVMGRGHARLVHVEEPHT 
MMP-13 GPQGLA-GQRGIV 
MT1-MMP IPES-LRAG 
uPA SGR-SA 
Cathepsin B SLLKSR-MVPNFN 
Cathepsin D SLLIFR-SWANFN 
Cathepsin L SGVVIA-TVIVIT 
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2. Protease Sensitive Liposomes 
2.1. Literature Review 
2.1.1. Liposome Discovery 
Liposomes were first described in 1961 (published 1964) by Alec Bangham while trying 
to determine a valid way to view lipid leaflets in the electron microscope.  Bangham prepped 
various mixtures of ovolecithin (a mixture of phospholipids derived from egg yolk), lysolecithin 
(lecithins that have been hydrolyzed to lack the C2 carbon chain, thus they posses lyctic activity 
against lipid bilayers), cholesterol, and/or saponin (any of a variety of plant derived sterols) 
(Figure 2.1.1) by dissolving the various mixtures in cholesterol, drying, hydrating in water and 
then suspending the lipids through either hand shaking or sonication. 
 
 
Figure  2.1.1 From top to bottom: 2-Palmitoyl 3-oleoylphosphatidylcholine, a common component 
of ovolecithin; 3-oleoylphosphatidylcholine, a common lysolecithin, cholesterol, and saponin. 
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When viewed in the electron microscope (negatively stained with potassium 
phosphotungstate), Bangham found that the lecithin and mixtures of lecithin and cholesterol 
formed spherical, multilayered particles of approximately 120 nm, similar to an onion (Figure 
2.1.2).  Lysolecithin did not show these multi-lamellar spheres, but rather homogenous 7 nm 
spheres, very typical of micelles, indicating that the lecithin structures were, in fact, significant 
and different from micelles.1   
 
 
Figure  2.1.2 Bangham’s lecithin only preparation as viewed in the electron microscope showing a 
multilamellar spherulite 
 
Bangham called the spherical, onion-like particles, spherulites, and determined that they 
were three-dimensional, enclosed, multi-walled spheres of lipid with water entrapped inside 
(Figure 2.1.3).  Treating these spherulites with lysolecithin or saponin broke down the structure 
and reverted to something more like micelles.1   
Bangham’s spherulites quickly became popular and were renamed liposomes.  
Liposomes (Figure 2.1.4) consist of a double layered membrane of phospholipids (often 
containing up to 50% cholesterol) that form in the presence of excess water.  The membrane 
wraps around to form a closed, sphere defining an interior and an exterior compartment.2  
Bangham showed that the interior compartment would have the same composition (solutes, etc.) 
as the exterior compartment which it was made in, as long as the solute is small enough to fit in 
the interior compartment.1  Liposomes were quickly shown to be substantially similar to 
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naturally occurring membranes3,4 and thus resistant to leakage of polar molecules (that is, 
molecules that could not easily adapt to the hydrophobic interior of the membrane).5,6  
 
 
Figure  2.1.3 Bangham’s drawing of the multi-lamellar membranes enclosing multiple 
compartments.  The graph shows the densities across the spherulites, demonstrating that they are 
three dimensional 
 
 
Figure  2.1.4 Phospholipids arrange themselves into a spherical bilayer to form a liposome. 
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2.1.2. Biological Uses of Liposomes 
Since liposomes (and the solutes that they trapped inside), could be separated from 
smaller, drug-like molecules simply by gel filtration or dialysis, the medical usefulness of the 
liposome soon became evident.2,7  Liposomes could regulate how quickly their contents were 
cleared from the body and where they ended up in the body, thus making excellent dosing and 
targeting regulators.8,9  Studies showed that the liposomes were stable in blood, not releasing 
their contents,10, 11, 12, 13, 14, 15 and when incubated with plasma constituents, they retained their 
spherical shape,16 although some small molecules (such as 5-fluoruracil or penicillin-G) were 
able to leak out through the membrane.17  
 
 
Figure  2.1.5 A multilamellar liposome with entrapped hydrophilic or hydrophobic molecules. 
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Some problems with in vivo use became evident, though, because the liposomes were 
quickly removed from the body, primarily by the reticuloendothelial system.10, 17, 18, 19 However, 
liposomes made with positively charged lipids lasted much longer in vivo than liposomes made 
with neutral or negatively charged lipids. When delivered intravenously, liposomal contents 
primarily ended up in the liver and the spleen, with smaller concentrations being delivered to the 
kidneys and lung, although, in some tests, this accounted for less than one percent of the 
delivered drug, with the majority being excreted in the feces.10, 20, 21, 22, 23, 24, 25, 26  
Some of the problems of quick removal were solved by using better defined preparations 
of lipid to make the liposomes.  Liposomes made from dipalmitoylphosphatidylcholine delivered 
a greater dosage of their contents than those made from undefined ovolecithin and this was 
hypothesized to be due to lower rates of hydrolysis of the dipalmitoylphosphatidylcholine 
compared to ovolecithin.27 Also, quick removal of the liposomes by the macrophages and 
monocytes of the reticuloendothelial system could be prevented by attaching a polyethylene 
glycol coating to the outside of the liposome (Figure 2.1.6).  Polyethylene glycol apparently 
creates a steric block around the outside of the liposome that does not interact with recognition 
molecules.  Since the polyethylene glycol does not interact with recognition molecules and it 
prevents the recognition molecules from reaching the liposomal surface, the liposomes are 
ignored by the reticuloendothelial system.  This preparation (liposomes coated in polyethylene 
glycol) has come to be known as stealth liposomes because of their ability to evade the 
reticuloendothelial system.28 
 
Figure  2.1.6 A stealth liposome showing the polymer coating 
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Although liposomes made from bovine brain phospholipids have been shown to have 
various unwelcome side-effects, liposomes made from most standard lipids do not show negative 
side effects in the body.30   
2.1.3. Drug Delivery Systems 
Many very useful drugs are generally toxic to the body, and can cause havoc when they 
interact with systems other than what they are targeted for.  An obvious solution to this problem 
would be to deliver the drug directly to the desired site, not allowing it to come in contact with 
the rest of the body, insuring that there is no indiscriminate toxicity.  To do this, drug delivery 
systems have been developed.31,32   
Drug delivery systems can overcome a variety of delivery and pharmacokinetic problems 
including poor pharmacokinetics, quick clearance or breakdown of the drug, poor solubility, 
unwanted general toxicity, or unwanted specific toxicity.32 A well known drug delivery system is 
Nicoderm, which, along with Nicotrol and Prostep are transdermal patches which release 
nicotine into the body creating a much better pharmacokinetic profile for cessation of 
smoking.33,34  Other drug delivery systems include Zolodex (an injectable polymer rod), Lupron, 
and Decapeptyl (both injectable polymer spheres), which have all been approved for use in long 
term delivery (better pharmacokinetics) of LHRH analogs to prostrate cancer.35, 36, 37  Oncaspar, 
PEG intron, and Neulasta are pegylated drugs (l-asparaginase, -interferon, G-CSF) that allow 
the drug to stay in circulation for a much longer period of time.32  Gliadel, an implantable wafer 
doped with BCNU, is used to control drug delivery to malignant gliomas.38 
All of the above drug delivery systems have no targeting effect, they are physically 
placed where the drug is desired (or, for the transdermal patches, the drug is delivered 
systemically).  In some cases, a targeting effect of the delivery system is desired because it is 
impractical or impossible to physically place a delivery device next to the target area.  The 
optimal drug delivery system would: 1) target the desired area, delivering the drug to the target 
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area and not systemically; 2) be easily administratable; and 3) release the drug in a way to 
maximize pharmacokinetic efficiency. 
2.1.4. Liposomes as Drug Delivery Systems 
Liposomes can make excellent drug delivery systems.39, 40, 41 They can carry large 
payloads of both hydrophilic (in the interior) or hydrophobic drugs (in the membrane) drugs.  
The membrane makes it very hard for the drug to diffuse out of the liposome, so they deliver 
very little of the drug systemically.  Liposomes are, themselves, non-toxic, and fortunately they 
naturally target tumor sites.  This build up, known as the EPR (Enhanced Permeation Retention) 
effect (Figure 2.1.7), is due to the leakiness of the blood vessels surrounding the tumor allowing 
the liposomes to extravagate into the tumor site.  The tumor is leaky because its nutritional needs 
lead it to rapidly develop new blood vessels without much quality control.  The tumor does not 
develop the lymphatic drainage system, though, meaning substances that enter the tumor site get 
trapped there.  This becomes like a small pool off of a big river – as debris floats down the river, 
it can float into the little pools to the side of the river and get stuck there, because there is no 
longer any current to continue moving the debris.  Thus, to reduce general toxicity, highly toxic 
chemotherapy drugs can be encapsulated in a liposome, where they will be prevented from 
interacting with healthy tissue and build up in cancerous tissue.31   
 
 
Figure  2.1.7 EPR Effect.  Blue cells are endothelial cells lining the blood vessels.  Red cells are 
cancer cells and green cells are healthy cells. 
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Although, liposomes demonstrate potential as drug delivery systems for cancer 
chemotherapy, there are a few continuing challenges.  First, although the drug builds up in the 
tumor, it is still encapsulated in the liposome.  The liposome must release the drug and let it 
interact with the cells to be of much use.  Although, this does eventually happen, it is a slow 
process, and hampers the effectiveness of the drug, leading to increased dosages to achieve the 
target level of the drug.  This slow leaking also happens in the rest of the body, so the drug is still 
delivered at low doses to the rest of the body.  Increased dosages leads to increased non-
discriminate leakage, which can cause the side effects that liposomes were created to prevent.  
Second, the liposome is not targeted specifically to the tumor.  Although, less prevalent than at 
tumor sites, liposomes are able to leak through the blood vessels at non-cancerous sites, 
delivering the drug to unwanted parts of the body.42, 43  
Extensive research has been done trying to solve these problems, especially focusing on 
immunoliposomes – liposomes conjugated to an antibody that recognizes the tumor cell.  The 
antibody causes the liposomes to become trapped at the cancer site, because they are targeted to 
a cancer antigen.  The antibody also encourages uptake of the liposomes by the cancer cells.  
Although, this method sounds good on paper, finding antibodies that distinguish healthy cells 
from cancer cells is quite challenging and, even if suitable antibodies are found, the antibodies 
themselves become a target of the RES system.44, 45  Other targeting techniques have been tried 
including, heat sensitive liposomes, pH sensitive liposomes, and metabolism targeted liposomes, 
although, the ‘magic bullet’ has not yet been found.45, 46, 47 
2.1.5. Tonicity and Osmotic Pressure 
Due to the tendency of systems to move toward equilibrium, solutions with high solute 
concentrations will tend to move solute molecules to solutions with low solute concentrations 
when they are in contact with each other.  When movement of the solute particles is inhibited, 
the solvent will move from one solution to the other to move the systems toward equilibrium.  
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This movement of water is called osmosis.  Because osmosis is a thermodynamically favored 
event, water, in osmosis, can actually flow against pressure gradients, until the entire system is at 
equilibrium; this is called osmotic pressure.  This can be easily demonstrated (Figure 2.1.8) by 
placing a semipermeable membrane (a membrane that is permeable to water, but impermeable to 
most solutes) in a U shaped tube and placing a concentrated solution on one side of the 
membrane and a dilute solution on the other.  Water from the dilute solution will flow through 
the membrane to the concentrated solution diluting it (and concentrating the dilute solution) until 
the osmotic pressure of the water is equal to the gravitational pressure of the water due to the 
height difference on either side of the tube.48 
 
 
Figure  2.1.8 A demonstration of osmotic pressure.  The tube on the left is pre-equilibrium.  The 
tube at the right is in equilibrium, showing that, at equilibrium, the system has developed 
gravitational pressure that balances the osmotic pressure 
 
The osmotic pressure of a system can be calculated using the equation: 
Π = RT Σ (ixMx)   (1) 
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 where Π is the ‘absolute’ osmotic pressure, R is the gas constant, T is the absolute 
temperature, i is the van’t hoff factor which, usually, equals the number of discrete particles the 
substance dissolves into, and M is the molarity of the solution.  The actual pressure exerted 
across a semipermeable membrane can be calculated by subtracting the ‘absolute’ osmotic 
pressure of the higher concentration from the ‘absolute’ osmotic pressure of the lower 
concentration side, Π1 - Π2.49   
 
 
Figure  2.1.9 Red blood cells in hypertonic, isotonic and hypotonic solutions, demonstrating how 
they shrink or swell 
 
Osmotic pressure is very important in biological systems as they are filled with high 
solute concentrations and semipermeable membranes.  Phospholipid membranes act as 
semipermeable membranes because they are resistant to ionic and polar compounds and large 
compounds, but allow small, non-polar compounds to cross freely.  Due to the large 
concentration of water and its small size, water can cross phospholipid membranes in biological 
systems, but most normal biological solutes cannot.  Since cells are defined by a phospholipid 
membrane, they must be very careful to regulate the osmotic pressure across their membranes.  If 
the osmotic pressure becomes too high either direction, it can destroy the cell (Figure 2.1.9).  
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When the cell is hypertonic (higher concentration of solutes unable to cross the membrane) 
compared to the interstitial fluid, the cell can swell and burst due to the pressure of the water 
flowing in pushing out on the membrane.  When a cell is hypertonic compared to the interstitial 
fluid, the cell can shrivel do to loss of interior pressure on the membrane from the water flowing 
out.49  
2.1.6. Liposomes and Osmotic Pressure 
The outer membrane of a liposome acts as a semipermeable membrane that allows water 
to pass through, but resists letting most hydrophilic solute molecules pass through, similar to a 
cell membrane.  Thus, liposomes are sensitive to osmotic pressure.   Liposomes that are 
hypotonic comparatively to the exterior compartment will shrink, while liposomes that are 
hypertonic will expand and may burst.50 
Theoretical studies on liposome swelling, pore formation, and bursting have determined 
that total destruction of a liposome is very unlikely.  More likely is the formation of pores in the 
membrane which allow efflux of the osmotically active substance, balancing the osmotic 
pressure.  The pressure at which this should occur can be derived theoretically from equation 1 
above.  Taking  to equal 1 -2, the influx of water into a hypertonic liposome should be: 
qinf = LpS(P)   (2) 
where qinf is the influx of water, Lp is the permeability coefficient of the membrane to 
water, S is the membrane area, and P is pressure from the membrane being stretched.50   
P can be determined from the following equation: 
P = 4 (/R0) (S/S0)   (3) 
where  is the elastic constant for the membrane (~100 - 1000 dyn/cm), R0 is the initial 
radius, S is the change in membrane area, and S0 is the initial membrane area.  When P = 
the influx of water stops because the pressure exerted by the membrane equals the excess 
osmotic pressure.  To relieve strain, on the membrane, the membrane may form pores.  When 
and how these pores are formed can be calculated theoretically as well.50   
 23 
Influx of water can also be expressed as: 
qinf = dV/dt   (4) 
where V is the change in volume of the liposome and t is time.  Taking into account 
equations 2 and 3 above, V can be calculated with respect to time: 
V = (2) (R04) [1-exp(-8 Lp t / R02)]  (5) 
From the equation, the maximum expansion of the membrane (Vmax) and the time it 
takes to expand (tmax) can be determined: 
Vmax =  R04 (6)
tmax = R02 / -8 Lp    (7)50 
In cases with large excess osmotic pressure, though, the membrane is unable to expand to 
the size necessary for P =  without breaking.  The energy of an expanded membrane can be 
calculated from: 
 (S)2/S0   (8) 
where  is the energy of the membrane.  Formation of a pore also requires energy, 
because the pore must either expose the hydrophobic core of the membrane to water, or have a 
very sharp curvature to prevent water from reaching the hydrophobic core.  The energy of pore 
formation can also be calculated from: 
p = 2r   (9) 
where p is the energy of the curvature of the pore,  is the linear tension of a pore (~2 x 
10-6 dyn), and r is the radius of the pore.50   
The energy of a membrane () that is originally expanded S and then forms a pore with 
area A has the following energy: 
 =  (S - A)2/S0 + 2 sqrt(   (10) 
being equation 8, modified by the loss of area of the pores, plus equation 9.  If S is 
known, then the only unknown is A, the area of the pore.  The system ‘chooses’ A in order to 
minimize the energy of the system.50   
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Calculations show that at low S values, pore formation is always unfavorable (curve 1 
above).  At larger S values, a minimum appears on the  vs. A curve, indicating that the 
formation of pores is favorable (Figure 2.1.10).   
 
 
Figure  2.1.10 The dependence of the vesicle energy on the pore radius for a vesicle of the radius of 
40 nm,  =0.1 J/m2, =2 X10-11 N; curves are parameterized by the relative excessive volume: (1) 
V/Vo=2.25%, (2) V/Vo=3%, (3)  V/ Vo=3.3%, (4) V Vo=4.2%. 
 
A minimum value of S (and thus V) and A (and thus r) have to be met for pore 
formation to be favorable.  The minimum values are given by: 
Smin/S0 = (3/4) (R0)2/3   (11) 
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Vmin/S0 = (9/8) (R0)2/3   (12) 
Amin/S0 = (1/4) (R0)2/3   (13) 
rmin/S0 = (R0)1/3   (14)50 
Using these equations, the membrane pressure at which pore formation can happen 
(Pmin) is given by: 
Pmin = (3 / R0) (R0)2/3   (15) 
If > Pmin then it would be expected that the liposome would form pores (as long as 
the liposome can temporarily absorb enough energy from the surroundings to overcome the 
barrier energy of pore formation, given by: 
0 = (3/ 4) (4 R02 / )1/3   (16) 
where 0 is the barrier energy).50 
Pore formation does not instantly bring the system into equilibrium, though.  The residual 
membrane pressure (Pr), causes the osmotically active substance to leak out through the pores, 
returning the system to equilibrium: 
Pr = 2 / R0 r   (17) 
qeff = Pr r3 / (18) 
where qeff is the efflux of the osmotically active substance and  is the viscosity of the 
solution.50 
Thus, if > Pmin then the entrapped osmotically active substance will leak out of the 
liposome into the solution.  To prevent leakage, ≤ Pmin or an external pressure source 
pushing in on the liposome must be introduced with:  
Pext ≥ - Pmin   (19) 
and thus: 
≤ Pmin + Pext   (20) 
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2.1.7. Osmotic Pressure and Drug Delivery 
Acquired drug resistance is a major obstacle in cancer therapy.  Acquired drug resistance 
is when the drug being used was once effective against the cancer, but the cancer has developed 
a resistance to the drug, rendering it ineffective.  A major mechanism of acquired drug resistance 
is drug transport, either a mechanism where the cell transports the drug out of the cell once it 
penetrates, or a mechanism where the cell does not allow the transport of the drug into the cell.  
Devising a mechanism to overcome this acquired drug resistance would greatly increase the 
effectiveness of chemotherapy.51, 52 
An effective way to overcome both types of drug transport resistance would be to deliver 
the drug directly inside of the cancer cell in large enough doses to overwhelm the drug 
transporters.  Liposomes are an excellent candidate to pursue for direct drug delivery because 
they have the potential to fuse membranes with the target cell, releasing the entrapped drug into 
the cell (Figure 2.1.12).53 
Although liposomes do naturally fuse with cell membranes, fusion is very slow because it 
is a kinetically hindered process – both membranes are in kinetically locked states.  In fact, it 
happens so slowly that most of the drug leaks out of the liposome before it fuses with any 
membranes, making this fusion useless to cancer therapy.   
Liposomes can be made to swell when a sufficient osmotic gradient is applied across the 
membrane.54, 55  In 1982, Cohen, et. al. demonstrated that causing a liposome to swell when it is 
near a planar membrane can cause rapid fusion with the membrane.  This is because the 
kinetically locked state of the membrane is disturbed by the swelling, enhancing the rate of 
fusion (a thermodynamically favored process).56  Two years later, Cohen demonstrated that 
swelling liposomes fused with cell membranes.  It was determined that a gradient of at least 200 
mosM was necessary for fusion and that the rate of fusion increased with increasing gradients to 
the point where the liposome burst.  Thus, liposomes that can be made to swell at the cancer site 
could be excellent drug delivery vehicles to overcome a basic drug resistance mechanism.57 
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2.1.8. Polymer Caged Liposomes 
Liposomes that deliver their contents when presented with a certain trigger are highly 
sought after for targeting various diseases.  In 2007, Lee et. al. described a method for coating 
liposomes in a cross-linked polymer shell.  The cross-linked polymer shell caused the liposomes 
to be sensitive to pH, delivering their contents at low pHs.  Lower pH is known to be associated 
with cancer cells due to their irregular glycolysis and respiration.  Unfortunately, the polymer 
caged liposomes (PCLs) did not release their contents until pH 2, while most tumor sites rarely 
get below 1 pH unit below physiological pH (~7.4).58   
 
 
Figure  2.1.11 Polymer Caged Liposome 
 
The polymer cage was not a total loss, though.  The cross-linked polymer did make the 
liposomes much more stable including preventing dissociation of the polymer from the 
membrane, preventing liposome degradation upon freezing or drying, and drastically slowed the 
natural leak of contents from the liposome.  PCLs may have a future in drug delivery due to their 
extremely stable properties.  If a suitable trigger can be found, PCLs could be the perfect 
delivery mechanism.58 
 
2.1.9. Protease Sensitive Liposomes 
In 2008, D. K. Srivasta’s group at North Dakota State University and Sanku Mallik’s 
group at University of North Dakota published a method for preparing liposomes that were 
sensitive to MMP-9 (gelatinase).  Shorts sequences of collagen were covalently modified with 
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lipids on their N-terminal ends and incorporated into liposomes through absorption.  MMP-9 was 
shown to trigger release of the liposomal contents.59  It is theorized that this release is triggered 
by MMP-9 distorting the triple helical structure of collagen during cleavage, distorting the 
membrane at the base of the sequences.  The distortion caused micropores to form in the 
membrane, releasing the contents.60 
 
 
Figure  2.1.12 MMP-9 sensitive liposome showing the triple helical structure extending from the 
surface of the liposome.  Inset – MMP-9 
 
Due to the mechanism of release, this method can only be used for collagenases 
(including gelatinases).  Other cancer associated proteases will not be able to use this mechanism 
because they cannot cleave multiple strands at once and do not cause major distortions in the 
three dimensional structure of short peptides during cleavage. 
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2.2. Methods and Theory 
2.2.1. Liposome Preparation 
Liposome preparation has remained, for the most part, substantially similar to the 
preparation used by Bangham when he discovered liposomes.  The basic process has five steps 
(Figure 2.2.1).  First, dissolve the lipids and cholesterol in an organic solvent in the desired 
ratios.  Next, evaporate the solution to dryness, making sure to fully remove all of the organic 
solvent, leaving a thin layer of mixed lipid/cholesterol on the bottom/sides of the container.  
Third, add an aqueous solution containing any molecules that are to be trapped in the liposome.  
Fourth, disperse the lipid film into the aqueous solution.  Finally, separate the liposomes from the 
unentrapped solution.1  
 
Figure  2.2.1 The basic scheme of liposome synthesis 
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The first two steps are still done nearly universally with very little deviation.  The third 
and the last step have a couple of variations, but are substantially the same.  The fourth step, 
though, dispersing the lipid film into aqueous solution, has many different variants, depending on 
the desired liposome characteristics.1 
The dispersion step is the most important step for determining many of the important 
properties of the liposomes including size, lamellarity, and monodisperseness.  The methods can 
be broken down into three broad categories based on how the liposomes are dispersed: 
mechanical dispersion, solvent dispersion, and detergent solubilization.1 
2.2.1.a. Mechanical Dispersion 
Mechanical dispersion was the first method used to prepare liposomes and is still the 
most widely used.  It also has the most variations in order to get different types of liposome 
preparations, primarily focused on determining whether multilamellar vesicles (MLVs), large 
unilamellar vesicles (LUV) or small unilamellar vesicles (SUV) are prepared, whether these 
preparations are monodisperse or polydisperse, and what the average size of the liposomes 
are.1,2 
The first method, used by Bangham, is simply hand shaking the hydrated lipid film.  This 
is a very simple procedure, but the small mechanical agitation caused by shaking is enough to 
disperse thin enough lipid films into the aqueous solution.  If the film is too thick (as might 
happen if the vessel is too small that the lipid was dried in, or if the temperature of drying was 
too high), glass beads can be added to the preparation during shaking.  Shaking at approximately 
60 RPM for 30 minutes will provide suitable liposome preparations.  Liposomes prepared by this 
method are MLVs and usually very polydisperse.1,2,3 
A similar method is called non-shaken vesicles.  The hydrated film is simply left to sit for 
a long period of time (two or more hours), and the lipid film swells into the solution.  After 
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swelling, the preparation is very gently agitated (swirled) to disperse the swelled lipid film into 
the solution.  This method can be used to prepare LUVs that are usually polydisperse.1,4 
In order to create somewhat more monodisperse, size defined MLVs, a method called 
pro-liposomes can be used.  Before drying the lipid/chloroform solution, a water soluble dry 
powder (such as sodium chloride) is added.  After drying, the lipid film is hydrated and shaken 
rapidly for less than a minute.  As the lipid film coating the particles swells and the particles 
dissolve in the aqueous solution, MLVs are created.  The MLVs size is influenced by the size of 
the substrate particles used, leading to more monodisperse preparations.1,5 
Another method for creating more monodisperse preparations is freeze drying.  The 
lipids, instead of being dissolved in chloroform are dissolved in an organic solvent suitable for 
freeze drying.  The solution is then freeze dried, leaving a foam-like film of lipid.  Upon 
hydration, the film is hydrated and shaken rapidly.  This forms MLV whose size is somewhat 
dependant on the size of the pores in the foam-like lipid film, leading to more monodisperse 
preparations.1,2 
To prepare small unilamellar vesicles, one method is to use a microemulsifier.  MLV are 
prepared by one of the methods above, and then the suspension is introduced in the 
microemulsifier.  The microemulsifier runs the solution at very high pressure through tubing.  At 
one point the channel splits into two, and then the device brings the channels back together at 
nearly right angles, causing the solutions to collide with each other at very high speeds.  The 
shearing forces causes the MLVs to break apart forming SUVs.  The size of the SUVs can be 
somewhat controlled by how many passes the MLVs take through the emulsifier.  The more 
passes the suspension makes, the smaller the SUVs’ size.1,6 
Another simple method for creating SUVs is to use a sonicator.  The hydrated lipid film 
is placed in a sonicator bath and sonicated for up to an hour with occasional shaking.  This 
method produces SUVs of extremely small sizes, and thus usually very monodisperse.  
Unfortunately, this method is often destructive to many samples.  It can destroy biological and 
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organic molecules, and at longer sonication times can even hydrolyze the lipid used to form the 
liposomes.1,2,7 
To create the most size defined SUVs two methods can be employed.  The first is using a 
French Press to shear already prepared multilamellar liposomes.  The high pressures of the 
French Press (up to 40,000 psi) create enormous shearing forces across the orifice.  These 
shearing forces create very monodisperse SUVs and the size can be regulated by the pressure 
used – the higher the pressure the smaller the size.1,2,8,9 
The second method is to do membrane extrusion with MLVs.  A polymer membrane 
(such as polycarbonate) is created that has well defined straight pores bored in it.  The MLV 
suspension is then pushed through this membrane at high pressure (500 psi or more).  The high 
pressure forces the larger MLVs to contort and break to fit through the pores.  After passing 
through the membrane several times (5-10), monodisperse SUVs are prepared with the average 
diameter being the pore size of the membrane.1,2,10 
A final mechanical method called freeze-thaw is used to create LUVs that entrap up to 
30% of the solution.  Liposomes are created by short sonication and then alternatively frozen and 
thawed several times (approximately ten times).  The freeze-thaw cycle causes the small 
unilamellar vesicles to fuse together creating larger and larger unilamellar vesicles.  Using this 
method, the largest LUVs can be prepared.1,11,12,13,14 
2.2.1.b. Solvent Dispersion 
Solvent dispersion is used in place of mechanical dispersion when either the lipids or the 
entrapped substance cannot withstand the high forces associated with mechanical dispersion.  All 
the mechanical dispersion methods, except hand-shaking and non-shaken liposomes, involve 
extremely high forces that can destroy some biological samples.1 
The easiest solvent dispersion method is ethanol injection.  The lipids are dissolved in 
ethanol instead of chloroform.  The ethanol solution is then rapidly pushed into an aqueous 
solution through a fine needle (ethanol concentration cannot exceed 7.5%).  This method gives 
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SUVs of about 25 nm in diameter.  Because of the low solubility of most lipids in ethanol, 
though, and the low maximum ethanol concentration of the final preparation, the liposomes 
formed by this method are extremely dilute.  Also, ethanol is often very hard to remove from the 
lipids.1,15 
A similar method is ether injection.  The lipids are dissolved in ether and then slowly 
pushed into an aqueous solution at a temperature at which the ether quickly evaporates off.  This 
method creates monodisperse LUV with size dependant on the speed of injection.  It does not 
have the problems associated with ethanol injection because the ether is evaporated off and does 
not stay in the solution.1,16,17 
2.2.1.c. Detergent Solubilization 
Detergent solubilization can give extremely monodisperse SUV and thus is sometimes 
used to create well defined liposome preparations.  The general method is to dissolve the desired 
lipids and a detergent in chloroform and then evaporate to dryness.  The film is then hydrated 
and micelles are formed.  The micelle suspension is then placed in dialysis tubing, and the free 
detergent removed by dialysis.  As the free detergent concentration drops, the micelles lose 
detergent into the solution.  As this continues, the micelles eventually run out of enough 
detergent to be stable and combine to form liposomes.  The size of the liposomes can be 
determined by the original lipid to detergent ratio.1,2 
2.2.2. Liposome Concentration 
There are several methods for assaying the concentration of a liposomal preparation.  
Nearly all are based on assaying the phosphate concentration from the phospholipids making up 
the liposome.  The three main methods of determining liposome concentration are the Bartlett 
assay, the Stewart assay, and optical emission spectroscopy (OES).2 
Each of these assays gives phospholipid concentration, not liposome concentration.  To 
get liposome concentration, the size of the liposomes must also be known and can be calculated 
from size and phospholipids concentration.2 
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2.2.2.a. Phospholipid Concentration 
Bartlett Assay 
The Bartlett assay is based on the molybdenum blue method for determining inorganic 
phosphate first introduced in 1914.  The assay is performed by hydrolyzing the phosphoester 
bonds (with perchloric acid), liberating inorganic phosphate from the lipids.  The inorganic 
phosphate is then converted to phosphomolybdic acid and then the molybdenum VI is reduced to 
molybdenum V to form a blue colored complex.  The reduction does not happen without the 
presence of the phosphate in the phosphomolybdic acid, so the intensity of the color formed is 
proportional to the concentration of the phosphate.  The concentration can then be assayed 
colorimetrically at 830 nm.2,18,19 
The procedure is as follows: 
Put liposome solution containing approximately 30 nmol of phospholipids in a test tube. 
Add .4 mL of perchloric acid. 
Incubate for 30 min at 180°C and then cool to room temperature. 
Add 1.2 mL of water, .2 mL of 5% (w/w) ammonium molybdate and 50uL amino-
naphthyl-sulfonic acid. 
Vortex the tube and then boil seven minutes. 
Read the absorbance at 830 nm. 
The Bartlett assay can be very precise, but is also easily interfered with.  The strengths of 
the assay are the preciseness of the assay, the disregard for type of lipid, and the low sample 
amount needed.  The drawbacks are extreme interference of that assay by other forms of 
inorganic phosphate in the system or other molybdenum active ions (sulfate, etc.), the time 
required for the assay, and the extreme preciseness needed in time, concentration and volume 
measurements needed for highly accurate results.2 
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Stewart Assay 
The Stewart assay was introduced by J.C.M. Stewart in 1980 to compensate for the 
drawbacks of the Bartlett assay.  The Stewart assay is not sensitive to other forms of phosphate 
in the system and is much faster and easier to perform.  The drawback of the system is, though, 
that different phospholipids do give different results, so the precise phospholipid make-up of the 
liposome must be known in order to get accurate results.2,20 
The procedure is based on the interaction of phosphate with ferrothiocyanate, which is a 
deep blood red color.  Ammonium ferrothiocyanate is very water soluble and partitions 
completely to the aqueous phase of an aqueous-organic mixture.  Phospholipids, on the other 
hand, partition nearly completely to the organic phase of an aqueous-organic mixture and can 
carry phosphate associated ferrothiocyanate into the organic phase.  The absorbance of the 
organic phase is proportional to the concentration of phospholipids in the system.2 
The procedure is as follows: 
Put liposome solution containing approximately .2 mg of phospholipids into a test tube. 
Add 2 mL of chloroform and 2 mL of 0.1 M ferrothiocyanate. 
Vortex vigorously for 30 seconds. 
Centrifuge at 1000 r.p.m. for 5 minutes. 
Remove the lower (organic) layer and take the absorbance at 485 nm.  
Optical Emission Spectroscopy 
A third method for determine the phospholipids concentration is OES.  To run OES, an 
aliquot of the liposome solution is simply diluted and put into the OES machine.  The 
phosphorus emission is recorded and translated back into phospholipids concentration.21 
The benefit of OES is that it is extremely simple, there are no reaction steps involved, and 
it is extremely accurate.  The drawbacks are that the assay uses an enormous amount of sample 
relative to the Bartlett or Stewart assays and requires special equipment (an ICP-OES machine or 
equivalent) that is often quite expensive.21   
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2.2.2.b. Calculation of Liposome Concentration 
Once the phospholipids concentration and the size of the liposomes have been 
determined, the liposome concentration can be calculated.  The calculation is done by calculating 
the number of lipid molecules in a liposome.  The number of lipid molecules in a liposome can 
be calculated by taking the area of the membrane (both the exterior and interior membrane) and 
dividing it by the area taken up by one lipid.  The surface area of the exterior membrane is given 
by: 
Ae = 4 r2 
where r is the radius of the liposome.  The surface area of the interior membrane is given 
by the same expression, but the radius is determined by subtracting the membrane thickness (h, ~ 
5 nm) from the exterior radius: 
Ai = 4  (r-h)2 
Thus the number of lipid molecules per liposome is given by: 
N = (Ae + Ai)/a 
where a is the head group area of the phospholipids.  The head group area is a property of 
the head group of the lipid (choline, ethanolamine, etc.), thus the lipid make-up must be known 
for this equation to be accurate.22 
The concentration of liposomes in the solution can then be found by dividing the 
concentration of phospholipids in the solution by the number of phospholipids per liposome: 
CL = Cpl / N 
where CL is the liposome concentration and Cpl is the phospholipid concentration.22 
2.2.3. Dynamic Light Scattering 
There are several methods for determining the size of a liposome preparation, but by far 
the most useful is dynamic light scattering.  Dynamic light scattering is a system based on the 
Rayleigh scattering of light (elastic scattering, as opposed to Raman scattering which is 
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inelastic).  By measuring fluctuations in the light scattering, the size of particles in the field can 
be calculated.23 
When an electromagnetic wave impinges on matter, the wave interacts with and 
accelerates the electrons.  The accelerated electrons in turn produce new electromagnetic waves 
which, in the absence of any actual electronic change in the particle, should be of the same 
wavelength as the incident wave but may be in a different direction or phase from the incident 
wave.  This is called elastic (Rayleigh) scattering.  Thus, when light interacts with matter, some 
of the light should be ‘redirected’ from its original course.  The intensity of light in any direction 
(except the direction of the incident beam) will be the sum of the scattered light in that direction 
from each particle in the incident beam.23   
It can be shown that, for optically homogenous matter (that is matter where the dielectric 
constant is exactly the same at any position), the sum of the scattered light in any direction 
(except the forward direction) is equal to zero, and thus, although the particles are scattering 
light, the total light scatter is zero.  This is because, in homogenous media, for every particle that 
scatters light in direction D with phase P, another particle can be paired with it that scatters light 
in direction D but with phase P + ½ period and the waves cancel out.  Thus, any observable light 
scatter must be from differences of dielectric constant within the media.23 
Because all particles in a fluid are constantly in motion, even in macroscopically 
homogenous media, the microscopic dielectric constants are not homogenous across the media.  
Thus, even macroscopically homogenous media can scatter light do to the distortion of 
microscopic domains of the dielectric constant by the movement of the particles.  This scattering 
is not constant, though, and changes rapidly as the particles move.  Thus the intensity of 
scattering in direction D at time T is a property of the instantaneous state of the system at time T 
and how fast the scatter in direction D changes is related to how fast the instantaneous state of 
the system is changing, and thus is related to how quickly the particles are moving.23 
Measuring the scattering intensity (Es) in direction D will thus give an average value A 
plus a time dependent value At, with At being the change in Es due to the random motion of 
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particles in the scattering area.  In a truly random system, At would be totally random and the 
correlation between any two time points, t1 and t2 would be zero.  In actual systems, though, 
although the motion of the particles appears totally random (due to the enormous number of 
collisions they may experience) the starting point of that movement is dependant on the previous 
state.  Thus, At is not a totally random variable and some correlation should be seen in the value 
of Es from t1 to t2 if t (t1-t2) is small.  Eventually, as t becomes larger, the correlation between 
Es at t1 and Es at t2 will become zero because the random motion of the particles will erase the 
systems ‘memory’ of its starting position.  As above, how quickly this ‘memory’ is lost is a 
function of how quickly the particles are moving.23 
It can be shown that the bulk property of a measured variable that is fluctuating around an 
average value and the average value is independent of when the measurement is taken is equal 
to: 
0
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where <A> is the average value, T is the length of time over which it is averaged, A(t) 
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where <A(0)A()> is the correlation between the measurement A(0) at time 0 and the 
measurement A() at time 0 + , for any time 0, T is the length of time over which the correlation 
is measured, A(t) and A(t+) are the values measured at time t and t+, and dt is the infinitely 
small spacing between measurements.  For measurements that are not infinitely close together, 
this becomes: 
1
1(0) ( ) lim
N
j j nN j
A A A A
N
 

   
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where N is the number of measurements taken, j represents the measurement at time t and 
j+n represents the measurement at time t+.23 
This function can be plotted against , and, as long as the variation around the average 
value is not periodic, the correlation function can be shown to have a maximum at  = 0 where 
<A(0)A()> = <A(0)A(0)> or <A2>.  The function also has a minimum at  = infinity where 
<A(0)A()> = <A(0)><A()> or <A>2.  Thus the correlation function is an exponential decay 
which follows the equation: 
2 22(0) ( ) exp
r
A A A A A 


    
where r is the correlation time of the function.23   
Making the definition: 
( ) ( )A t A t A    
the exponential decay function reduces to: 
2(0) ( ) exp
r
A A A    


  
This formula can be used to mathematically represent the correlation between At (the 
time dependent change in Es) from above.  Thus the scattering of light by particles can be 
defined by correlation time, r.  The value of r determines how quickly the exponential function 
decays.  Since, as shown above, the correlation of At between any two time points gets smaller as 
the particles lose their ‘memory’ of where they started, the speed of decay in the correlation is 
dependant on how quickly the particles are moving.  Thus r is dependant on the speed of motion 
of the particles.23 
In a fluid, particles have rapid, random motion due the massive number of collisions they 
have with other particles in the fluid; this motion is called Brownian motion.  The speed of 
Brownian motion can be shown to depend on the size of the particle.  Consider a colloidal 
suspension with small solvent molecules and large colloid particles, thousands of times larger 
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than the solvent.  The small solvent molecules will interact with several other solvent molecules 
at any given instant.  A disproportion in interaction on one side or the other will impart a new 
momentum to the solvent molecule.  The same happens for the colloid particles, but because of 
their larger size, they interact with hundreds of thousands more solvent molecules that a single 
solvent molecule does.  Thus, the random averaging of the collisions in more close to zero and 
the ratio of the disproportionate force to the mass of the particle is much smaller.  Also, the 
larger particle has more drag through solvent molecules which also retards Brownian motion.  
The summation of the lower force/mass ratio and the larger drag shows that the Brownian 
motion of spherical particles is only related to their radius (it is not related to mass because the 
mass term is a multiplier in the friction term and a divisor in the applied force term, in low 
Reynolds’s number situations, these terms cancel).  Thus particles with larger radius move 
slower than particles with slower radius.23 
In a colloidal suspension, the dielectric constant changes at the interface between the 
solvent and the suspended particle, making suspended particles very good scatterers.  Thus, in a 
colloidal suspension, nearly all of the scattered light is due to the larger suspended particles.  
Since the properties of the scattered light can be represented by the correlation time, r, and the 
correlation time is a function of the speed of the particles, the scattered light can determine the 
size of the suspended particles based on how quickly they are moving.23   
This is mathematically modeled with the following equation: 
t
r
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where n0 is the refractive index of the suspension,  is the wavelength of light used for 
scattering,  is the angle at which the scattering was measured, and Dt is the diffusion constant.24 
Dt in turn can be related to the mobility of the particle by the following: 
TkD Bt 
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where  is the mobility of the particle (or the terminal drift velocity in an applied force), 
kB is the Boltzmann constant, and T is the absolute temperature.  Mobility, in turn, is the 
reciprocal of the drag coefficient (): 
HR 6
 
where  is the viscosity of the sample and r is the hydrodynamic radius of the particle.  
Thus the radius can be found by:24 
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2.2.4. Liposome Integrity and Delivery 
One of the most important aspects to measure when using liposomes as a drug delivery 
device is when, where, and why they deliver their contents.  This can be modeled using a variety 
of assays to determine how much of the liposomal contents have leaked out in response to some 
variable.  Early assays for liposome leaking were based on simple colorimetrically active 
substances.  The absorbing species was incorporated into the liposome during synthesis and any 
unincorporated absorbing species were removed by gel filtration or dialysis.  The liposomes were 
then exposed to whatever variable was desired and then the liposomes were separated from the 
leaked contents, often by centrifugation.  The concentration of the leaked contents was 
determined colorimetrically and the amount of leaking was determined.  The marker was chosen 
to have the following properties: 
it does not pass through intact membranes 
it is highly water soluble 
it has low solubility in organic media 
it does not associate with the membrane in any way so as to destabilize or aggregate them 
it can be easily separated from liposomes2 
Currently, simple colorimetric assays are used less often because they are time 
consuming and the separation techniques (centrifugation) themselves can cause the liposomes to 
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leak, making it hard to separate leaking from the applied variable and leaking from the 
separation.  There are three main methods for assaying the leak rate of liposomes without having 
a separation step involved: dye interaction, fluorescence self-quenching and enzymatic 
determination.2 
2.2.4.a. Dye Interaction 
The dye interaction application is the closest to the earlier colorimetric assays.  A 
colorimetric dye is trapped in the liposomes that changes its absorbance properties in response to 
another substance that obeys the rules above.  The prime example of this is Arsenazo III.  Under 
standard conditions Arsenazo III has an absorbance maximum at 560 nm, but in the presence of 
calcium, the absorbance maximum shifts to a doublet at 606 and 660 nm.  Arsenazo III is 
incorporated into liposomes without calcium.  The liposomes are then diluted into a buffer 
containing calcium and whatever variable is being tested is applied.  The absorbance at 660 nm 
is then measured to determine the amount of released Arsenazo III that has been able to interact 
with calcium.  This method works well, because it does not require any separation step, but 
sometimes (as in the case of calcium) the interaction partner can induce its own changes in many 
membranes, thus occluding the actual effect of the variable.2  
2.2.4.b. Fluorescence Self Quenching 
Certain fluorescent dyes at high concentrations will form stable homocomplexes that 
change the absorbance profile of the dye and quench the fluorescence.  This can be used to create 
liposomes that will only fluoresce once the entrapped dye is released.  The two most common 
fluorescent dyes used for this are carboxyfluorescein (CF, with similar fluorescence properties to 
fluorescein, but more soluble in water allowing it to obtain quenching concentrations) and 
calcein.  To prepare self-quenched liposomes with CF, the liposomes are prepared in the 
presence of 100mM or more CF (at concentrations above 3mM, carboxyfluorescein shows 
almost no fluorescence).  Unentrapped CF is removed by gel filtration and the liposomes are 
diluted to a dilution where total CF is between 3 and 30uM.  The desired variable is then applied 
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and fluorescence can be measured from the CF.  In the absence of leaking, the CF remains 
trapped inside the liposomes at concentrations exceeding 100mM and shows no fluorescence.  
Upon leaking, the CF is drastically diluted and fluoresces strongly.  Thus the percent released is 
proportion to the total fluorescence of the sample.2   
This method is extremely useful, because it can nearly instantly determine the amount of 
contents released without any separation step or need for secondary reactants outside the 
liposome that may interfere with the liposome or variable being tested.2 
2.2.4.c. Enzymatic Assays 
A final method for percent release assays is enzymatic determination.  Either an enzyme 
or an enzymatically active substance is entrapped inside the liposome.  Once the liposomes are 
purified, they are diluted into a solution containing the counterpart enzyme or substrate.  Upon 
leaking of the liposomes, the enzyme and substrate come together and the product is formed.  If 
the product is colorimetrically active, the increase in absorbance can be directly measured.2 
A common example is glucose and hexokinase/glucose-6-phosphate dehydrogenase.  
Glucose is entrapped in the liposomes.  Upon leaking, the glucose is converted to 6-
phosphogluconate with the reduction of NADP to NADPH.  The increase in concentration of 
NADPH can be measured at 340nm.  This method is useful for measurements that do not require 
separation, but require many reactants and enzymes to be used outside the liposome that may 
interfere with the variable being tested.  It is also not instantaneous as the carboxyfluorescein is 
above, and thus is unsuitable for kinetic measurements.2 
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2.3. Experimental 
2.3.1. Materials 
All lipids obtained for liposome synthesis were of greater than 99% purity.  1,2-
dipalmitoyl-sn-glycero-3-phosphocholine (DOPC) was purchased from Avanti Polar Lipids, Inc. 
(Alabaster, AL).  1,2-dioleoyl-sn-glycero-3-phosphocholine (DPPC) was purchased from Sigma 
Life Science.  Cholesterol was purchased from Pfaltz and Bauer (Waterbury, CT).  Lipids were 
dissolved in chloroform upon receipt and stored at -20°C to prevent degradation or absorption of 
water. 
10X HEPES buffered saline (10X HBS) was prepared as .012M 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), 1.36M sodium chloride and .045M potassium chloride.  
HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, >99.5% purity) was purchased 
from Sigma Life Science.  Sodium chloride and potassium chloride (>99% purity) was purchased 
from Fisher Scientific.  5(6)-carboxyfluorescein (CF, >99% pure) was purchased from Sigma 
Life Science and was stored at -20°C upon receipt.  
Peptides GSGRSAGC and GSGRSAGK (synthetic, >80% pure) were purchased from 
GenScript (Piscataway, NJ).  3-(ethyliminomethyleneamino)-N,N-dimethyl-propan-1-amine 
hydrochloride (EDC*HCl) was purchased from Sigma Life Science. 3-(ethyliminomethylene-
amino)-N,N-dimethyl-propan-1-amine methyliodide (EDC*MeI) was purchased from MP 
Biomedicals (Solon, OH).  Hydroxybenzotriazole (HOBt) was purchased from Fisher Scientific.  
Both peptides and all coupling reagents were stored at 4°C upon receipt.  Sodium polyacrylate  
(average mass 5100 Da) was purchased from Aldrich. 
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2.3.2. Synthesis of Cholesterol-Tagged, Protease-Sensitive Polyacrylic Acid 
2.3.2.a. Acid Functionalized Cholesterol 
1.15 g of cholesterol (3 mmol, 1 eq.) was dissolved in 30 mL of THF along with 0.72 g 
NaH (30 mmol, 10 eq.) and the reaction was stirred one hour.  At the end of one hour, 10 mL of 
diethyl ether was added and the reaction was stirred 1.5 hours.  After stirring, 1.76 g of tertiary 
butyl 2-bromoacetate (9 mmol, 3 eq.) was added to the solution and the solution was refluxed for 
15 hours.  After refluxing, 20 mL of water was added and the product was extracted with 3 x 25 
mL diethyl ether.  After extracting, the ether was evaporated off, and the sample was dissolved in 
10:1 hexane:ethylacetate (vol/vol) and run over a 0.5 in. x 15 in. silica gel column.  The product 
eluted after 40 mL.  NMR was taken to confirm product and can be seen in  Appendix A. 
To deprotect the acid group, 3 mL of formic acid (79.5 mmol, 26.5 eq.) was added to the 
product isolated above with 7 mL of diethyl ether.  The solution was refluxed for 2 hours and 
then the diethyl ether and formic acid was evaporated.  NMR was taken to confirm product and 
can be seen in  Appendix A.   
2.3.2.b. Amine Functionalized Polyacrylic Acid 
5 g of sodium polyacrylate (5100 Da average weight, 1 equivalent) and .38 mL 2-(2-
chloroethyl)oxirane (5 equivalents) were dissolved in 20 mL of dry DMF.  The mixture was 
stirred for 72 hours at room temperature and then 1 mL of 18M NH4OH (18 equivalents) was 
added drop wise to the mixture.  The solution was then stirred another 24 hours at room 
temperature and then rotovapped to dryness.  Once dry, the powder was put under high vacuum 
for 72 hours to remove any remaining solvent.   The resulting white powder was stored under 
nitrogen. 
2.3.2.c. Condensation 
2.5 mg (1 equivalent) of the acid derivatized cholesterol from  2.3.2.a was dissolved in 
500 L dry DMF and cooled to 0°C.  1.7 mg (1 equivalent) EDC*HCl was added and the 
solution was stirred at 0°C for 30 minutes.  1 mg (1.33 equivalents) HOBt was then added and 
 46 
the solution was stirred at room temperature for three hours.  4 mg (1 equivalent) of the peptide 
GSGRSAGC was added to the mixture and the solution was stirred overnight to give the 
cholesterol-peptide complex (not purified). 
After 24 hours, the mixture was again cooled to 0°C.  1.7 mg (1 equivalent) EDC*HCl 
was added and the solution was stirred at 0°C for 30 minutes.  1 mg (1.33 equivalents) HOBt 
was then added and the solution was stirred at room temperature for three hours.  29 mg (1 
equivalent) amine functionalized polyacrylic acid from  2.3.2.b was added to the mixture and the 
mixture was stirred overnight.  The mixture was then rotovapped to dryness and the resulting 
powder was put under high vacuum for 72 hours to remove any solvent remaining.   
2.3.3. Liposome Preparation 
2.3.3.a. Bare Liposomes 
Bare liposomes were prepared according to standard methods.1  To prepare bare 
liposomes (BL), DPPC or DPPC and DOPC (various ratios) was dissolved in 600 L of 
chloroform along with cholesterol (various ratios).  The solution was vortexed for 30 seconds to 
insure even distribution of the lipids.  The chloroform was then evaporated off at 50°C under 
blowing air.  Once the lipid film was dry, it was placed under high vacuum for 1 hour to remove 
any remain chloroform.   
After drying, the lipid film was hydrated with 600 L of nX HBS (prepared by diluting 
10X HBS) with or without 100 mM CF.  The hydrated film was vortexed for 3 minutes, 
sonicated for 1 minute, and then vortexed again for two minutes to suspend the lipid film in the 
HBS.  The suspension was then put through ten freeze-thaw cycles, 8 minutes/cycle (4 cold/4 
hot) with the high temperature being 50°C and the low temperature being -80°C. 
After the last freeze-thaw cycle, the suspension was warmed to 50°C.  The suspension 
was then forced through two polycarbonate membranes with 200 nm pores using an Eastern 
Scientific, Inc. mechanical extruder.  After passing through the membranes ten times, the 
liposome preparation was purified from the unentrapped analytes by passing through a 15 cm x 1 
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cm Sephadex G-50 gel filtration column.  The cloudy fraction that comes out with the void 
volume was collected.  Liposome preparation was verified by dynamic light scattering of the 
resulting suspension.  The suspension was stored at 4°C until used. 
2.3.3.b. Polymer Incorporated Liposomes 
Polymer incorporated liposomes were prepared similarly to the procedure in Lee, et. al.2   
To prepare polymer incorporate liposomes (PIL), protease sensitive polyacrylic acid from  2.3.2 
(various amounts) was added to BL from  2.3.3.a.  The mixture was heated to 37.5°C and rocked 
overnight.  The PIL were then separated from unincorporated polymer by passing over a 15 cm x 
1 cm Sephadex G-50 gel filtration column.  The cloudy fraction that comes out with the void 
volume was collected.  PIL preparation was verified by dynamic light scattering.  The suspension 
was stored at 4°C until needed. 
2.3.3.c. Polymer Caged Liposomes 
Polymer caged liposomes were prepared similarly to the procedure in Lee, et. al.2  To 
prepare polymer caged liposomes (PCL), PIL from  2.3.3.b were heated to 37.5°C.  One 
equivalent of EDC*MeI (in relation to the polyacrylic acid residues, assuming 100% 
incorporation) was added to the suspension and the suspension was rocked for two hours at 
37.5°C.  The peptide GSGRSAGK or ethylene diamine was then added to the suspension 
(various ratios to polyacrylic acid residues), and the suspension was rocked at 37.5°C overnight.  
The PCL were separated from reagents by passing over a 15 cm x 1 cm Sephadex G-50 gel 
filtration column.  The cloudy fraction that comes out with the void volume was collected.  PCL 
preparation was verified by dynamic light scattering.  The suspension was stored at 4°C until 
needed. 
2.3.4. Liposome Concentration 
Liposome concentration was assayed by determining the phospholipid concentration of 
the suspension using the Stewart Assay or ICP-OES.  
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2.3.4.a. ICP-OES 
The liposome sample was diluted to approximately 5 mg/L phosphate content.  Standards 
were prepared at 1, 2, 4, 6, 8, and 10 mg/L phosphate from DPPC.  25 mL of the standards and 
the samples were fed into an ICP-OES and the sample was compared to the standard curve to 
determine phosphate concentration.   
2.3.4.b. Stewart Assay 
The Stewart Assay was adapted from Lasch, et. al.3  Iron (III) thiocyanate ion was 
prepared from 27.03 g (0.1 mol) FeCl3 and 30.4 g (0.045 mol) NH4SCN and diluted to 1 L in 
water to give 0.1 M Fe(SCN)(H2O)52+.  One hundred microliters of either BL, PIL, or PCL were 
added to 2 mL of the Fe(SCN)(H2O)52+ solution and 2 mL of chloroform.  Standard were made 
with DPPC to cover the range of possible concentrations.  The mixtures were then vortexed 
vigorously for 1 minute and centrifuged at 2000 RPM for 10 minutes to separate the organic and 
aqueous layers.  The lower organic layer was then removed and 725 L of the organic layer was 
diluted to 1.45 mL with chloroform.  The absorbance at 485 nm and 690 nm was taken.  The 
value ABS(485) – ABS(690) was plotted against the standard curve to determine phospholipid 
concentration. 
2.3.5. Liposome Sizing 
Once the liposome concentration was found, liposomes were diluted to 1 mg P/L in 
isotonic buffer.  The liposome suspension was allowed to stabilize to room temperature and 
dynamic light scattering measurements were taken with a Brookhaven ZetaPlus Particle Size 
Analyzer.   
2.3.6. Carboxyfluorescein Concentration 
A percent encapsulation procedure was adapted from Lasch et. al.3  In order to determine 
percent encapsulation, 100 L of the liposome suspension was added to 100 L of 5M Brij-58.  
The solutions were mixed well and then diluted to 2 mL.  Serial dilutions were made until the 
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absorbance at 480 nm was less than one.  The absorbance at 480 nm and 690 nm were then 
measured.  The concentration of carboxyfluorescein was determined by the ABS480 – ABS690 as 
compared to a standard curve.  
2.3.7. Carboxyfluorescein Release Assay 
2.3.7.a. Pressure Sensitive Carboxyfluorescein Release 
Bare liposomes, polymer incorporated liposomes, and polymer caged liposomes were 
prepared as above in 10 X HBS.  Various dilutions of HBS were then made by diluting 10 X 
HBS with 0.012 M HEPES Buffer to make the solutions have the desired pressures against 10X 
HBS.  The desired samples were then diluted so that the sample contained 2 mol 
carboxyfluorescein in 2 mL in each sample.  The diluted samples were incubated at 37.5°C for 
the desired time and then fluorescence measurements were taken to determine percent release.  
Carboxyfluorescein was excited at 450 nm and the fluorescence was recorded from 470 nm to 
620 nm.  Total fluorescence was determined by summing the fluorescence from 470 nm to 620 
nm.  Curves of total fluorescence verses pressure were fitted using a logistic function: 
( ) D E
AF
B Ce 
 

 
where  is the difference in osmotic pressure and A, B, C, D, and E are fitting constants.  
The fluorescence verses pressure curves were then compared to determine the difference in 
pressure sensitivity of various liposome preparations. 
2.3.7.b. Urokinase Sensitive Carboxyfluorescein Release 
Using the results from the pressure sensitivity studies, the ideal osmotic pressure was 
determined for various liposome preparations.  Bare liposomes, polymer incorporated liposomes 
and polymer caged liposomes were prepared as above in a concentration of HBS that would give 
the ideal osmotic pressure for that preparation versus 1X HBS (nx HBS- 1x HBS = ideal osmotic 
pressure or 1x HBS + ideal osmotic pressure = nx HBS).  These liposome preparations were then 
diluted into HBS with various amounts of uPA so that the final concentration of HBS was 1x and 
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the final content of carboxyfluorescein was 2 mol in 2 mL.  The diluted samples were incubated 
at 37.5°C for the desired time and then fluorescence measurements were taken to determine 
percent release.  Carboxyfluorescein was excited at 450 nm and the fluorescence was recorded 
from 470 nm to 620 nm.  Total fluorescence was determined by summing the fluorescence from 
470 nm to 620 nm.   
 51 
2.4. Results and Discussion 
2.4.1. Goals 
The goal of the current study is to prepare a drug delivery system that will more 
selectively target cancer cells through their protease signature.  This will be done by synthesizing 
a block copolymer composed of a short peptide sequence sensitive to a cancer specific peptidase 
and polyacrylic acid.  An anchor (either a fatty acid or cholesterol) will be attached to the 
polymer and the polymer will be incorporated into liposomes.  The polymer will be cross-linked 
with a cross-linker that is also sensitive to the peptidase.  When formed under hypertonic 
conditions, liposomes can swell and burst, rapidly releasing their contents into the surrounding 
media.  The cross-linked polymer will be able to stabilize the hypertonic liposome.  Upon 
reaching the cancer cell, the cancer specific peptidase will degrade the cross-links and cleave the 
polymer from the liposome, causing the liposome to swell from the osmotic pressure.  The 
swelling will cause the liposome to either fuse with nearby cell membranes, delivering the drug 
directly into the cell, or burst, delivering the drug at the cancer cell site. 
To accomplish this goal, the following steps must be accomplished: 
1. Bare liposomes must be successfully prepared 
2. Polymer incorporated liposomes must be successfully prepared 
3. Polymer caged (crosslinked) liposomes must be successfully prepared 
4. Polymer caged liposomes must show significant resistance to osmotic pressure 
induced leakage verses bare liposomes 
5. Polymer caged liposomes must show significant increase in percent release when 
exposed to urokinase plasminogen activator 
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2.4.2. Polymer Caged Liposomes 
2.4.2.a. Bare Liposomes 
Bare liposomes were initially prepared with 5.2 mg DPPC (55.4 mol%) and 2.1 mg 
Cholesterol (44.6 mol%).  The lipids were dissolved in 300 L chloroform and dried under argon 
at 50 °C.  The lipids were then hydrated in 300 L of 1x PBS (1x Phosphate Buffered Saline, 
0.136 M NaCl, 0.0045 M KCl, .012 M PO43- buffered to pH 7.4.  1x PBS is isotonic with blood 
serum and thus is a commonly used buffer for biological studies) and prepared as detailed above 
in  2.3.3.a.  The liposomes were then diluted to 10% of the concentration post-preparation in 1x 
PBS and dynamic light scattering measurements were taken to verify liposome preparation.  Four 
separate samples were measured (Table  2.4.1) with a mean diameter of 136.72 nm and a standard 
deviation of 0.82 nm (0.60%) indicating that liposomes were successfully prepared by this 
method.  Considering the very low standard deviation across samples, this would indicate that 
the liposomes are very monodisperse. 
 
Table  2.4.1 Dynamic Light Scattering Results: Bare Liposome Synthesis 
 Correlation Time (ms) Diameter (nm) 
1 0.8023 137.73 
2 0.79227 136.01 
3 0.79839 137.06 
4 0.79275 136.09 
Mean 0.79642 136.72 
St. Dev. 0.00480 0.82 
% St. Dev. 0.60% 0.60% 
 
2.4.2.b. Liposome Concentration 
Initial liposome concentration measurements were attempted by HPLC using a reverse 
phase C-18 column with solvent A being water and solvent B being chloroform.  Standards were 
prepared for DPPC in chloroform (330 g/mL, 230 g/mL, 130 g/mL, 33 g/mL, and 
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17g/mL) and for cholesterol in chloroform (140 g/mL, 98 g/mL, 56 g/mL, 14 g/mL and 7 
g/mL).  The prepared liposome sample was diluted 50 times with chloroform to a maximum 
(considering 100% capture of cholesterol and DPPC in the liposomes) of 330 g/mL DPPC and 
140 g/mL.  Unfortunately, the available HPCL did not show a linear response to the DPPC or 
cholesterol standards, so the HPLC as a concentration measurement had to be abandoned.   
ICP-OES (Inductively Coupled Plasma – Optical Emission Spectroscopy) has been used 
before to determine lipid concentration in water by measuring the phosphorous signal (nearly 
every biological lipid (except cholesterol) is a phospholipid, thus the concentration of lipid in the 
sample can be measured by measuring the phosphate signal).  To use ICP-OES, though, there 
needs to be no other source of phosphate in the system, so a phosphate buffered system (such as 
PBS) is unsuitable as the phosphate in the buffer will overwhelm any signal from the 
phosphorous in the lipids.  To correct for this, liposome samples were hydrated in 1x HEPES 
Buffered Saline (1x HBS, 0.136 M NaCl, 0.0045 M KCl, .012 M HEPES buffered to pH 7.4, still 
isotonic with blood serum) instead of 1x PBS for the remainder of the studies.   
Standards were prepared for ICP-OES at 0, 4, 8, 12, 16, and 20 mg Phosphorous/L using 
DPPC in 1x HBS and samples were prepared by diluting in 1x HBS until the maximum 
phosphorous concentration (assuming 100% capture of DPPC) was 14 mg/mL.  ICP-OES 
showed a linear curve with DPPC concentration and worked well for measuring the lipid 
concentrations.  Due to lack of access to an easily available ICP-OES (inducing extra time and 
expense) and the enormous sample sizes needed (50 mL for each standard and each sample, also 
inducing extra time and expense), the deviation in capture over several liposome preparations 
was studied to determine if the lipid concentration needed to be measured each time.  As can be 
seen in Table  2.4.2, the standard deviation in the concentration was very high (26.91 %).  Thus, 
ICP-OES was also abandoned as a lipid measurement technique in favor of easier, cheaper and 
quicker methods.  
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Table  2.4.2 Deviation in Liposome Concentrations 
Sample 
Counts 177.434nm 
(arbitrary units) 
mg/L 
Phosphorous mol/L DPPC 
Standard 1 0.00 0.00 0.00E+00 
Standard 2 20.00 4.00 1.29E-04 
Standard 3 40.00 8.00 2.58E-04 
Standard 4 60.00 12.00 3.87E-04 
Standard 5 80.00 16.00 5.17E-04 
Standard 6 100.00 20.00 6.46E-04 
Sample 1 28.72 5.74 1.85E-04 
Sample 2 50.26 10.05 3.25E-04 
Sample 3 44.88 8.98 2.90E-04 
Sample 4 57.97 11.59 3.74E-04 
Sample 5 62.46 12.49 4.03E-04 
Sample Mean 48.86 9.77 3.16E-04 
Standard Deviation 13.15 2.63 8.49E-05 
% Standard Deviation 26.91% 26.91% 26.91% 
 
Another method for quantifying the lipid concentration in a sample based on the 
phosphate in phospholipids is the Stewart Assay as described above in the experimental 
(2.3.4.b).  Standards were prepared with 0, 2.5, 5, 7.5, 10, 11, 22, 33, 44, 50, 75, 150, 225, and 
300 mg Phosphorous/L with DPPC in 1x HBS.  Samples were prepared by adding 100 L of the 
liposome preparation or standard to 2 mL of the Fe(SCN)(H2O)52+ solution and 2 mL of 
chloroform (as above).  Absorbance of the Fe(SCN)(H2O)52+ complex was taken at 480 nm and 
to construct a better curve, the absorbance was corrected by subtraction out background 
absorbance of the sample as measured at 690 nm.  The curve of ABS480 – ABS690 versus 
concentration was linear over the entire concentration range (Figure 2.4.1). 
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Figure  2.4.1 Stewart Assay Standards 
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The Stewart Assay uses much less sample (50 – 100 L versus 500 L) and can be 
performed on the bench with a simple spectrometer.  Thus, the Stewart Assay was used for the 
rest of the studies in this paper for liposome concentration.   
2.4.2.c. Polymer Integrated Liposomes 
A block copolymer (Figure  2.4.2) containing a cholesterol anchor, a short peptide 
sequence comprised of the uPA consensus sequence and some spacer peptides, and polyacrylic 
acid was synthesized as described above in the experimental (2.3.2). 
 
Figure  2.4.2 The synthesized block copolymer.  Red is the cholesterol anchor, blue is the uPA 
consensus sequence, purple is the polyacrylic acid. 
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The block copolymer was integrated into bare liposomes made in 10x HBS + 100 mM 
carboxyfluorescein as described above in  2.3.3.b by adding bare liposomes constituting 2 mol 
of DPPC (1 equivalent) to 20 L of the prepared polymer at .2 mg/L (4 mg, 0.32 equivalents) 
and diluting to 600 L with 10x HBS.  A control batch was also made by adding bare liposomes 
constituting 2 mol of DPPC to 20L 10x HBS and diluting to 600 L with 10x HBS.  Three 
preparations of the sample and the control were made.  After incubating and purifying and taking 
concentration measurements, the preparations were diluted to 1 mg phosphorous/L and DLS 
measurements were taken.  Each sample was sampled four times for DLS measurements.  The 
polymer integrating into the liposome should increase the hydrodynamic diameter because it 
adds size and drag to the liposome.   
As can be seen in Figure 2.4.3, the sample containing the polymer did register slightly 
larger than the control.  Doing a t-test on the results shows p = 0.03, indicating that there is a 
very low probability that the samples are the same.  Considering the increase in size was in the 
expected direction and the significance indicated by the t-test, it can be safely said that the 
polymer incorporated liposomes were successfully prepared. 
 
Figure  2.4.3 Polymer Incorporated Liposome DLS Measurements 
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Table  2.4.3 Polymer Incorporated Liposome DLS Measurements. 
Sample Measurement 1 2 3 4 Mean St Dev % St Dev 
Control 1 112.55 111.76 113.38 117.30 113.75 2.46 2.16% 
Control 2 114.06 114.37 108.70 114.42 112.89 2.80 2.48% 
Control 3 107.32 113.34 113.17 110.48 111.08 2.83 2.54% 
        
Sample 1 116.03 118.80 115.48 115.73 116.51 1.54 1.32% 
Sample 2 116.03 110.92 113.83 121.69 115.62 4.56 3.94% 
Sample 3 113.25 113.38 111.46 116.56 113.66 2.12 1.87% 
 
Table  2.4.4 PIL DLS Summary 
Sample Mean St Dev % St Dev 
PIL C 112.57 2.70 2.40% 
PIL S 115.26 3.01 2.61% 
 
2.4.2.d. Polymer Caged Liposomes 
The cross-linker used was another short peptide sequence, GSGRSAKG, that contains 
two amines (the N-terminal amine and the lysine amine) and the uPA consensus sequence 
between them (GSGRSAGC).  This was used so that uPA should be able to cleave both the 
polymer and the cross-links to more fully degrade the polymer cage.  To prepare polymer caged 
liposomes, PILs were prepared as above (2.4.2.c) and the integrated polymers were crosslinked 
as described in 2.3.3.c.  PILs constituting 640 nmol DPPC (1 equivalent) were added to 5.8 mg 
EDC*MeI (19.5 mol, 30 equivalents) and incubated 2 hours.  After incubating, 20 L of 
crosslinker at 40 mg/mL (36 nmol, .056 equivalents, 34% crosslinking assuming 100% reaction) 
was added and the preparation was incubated overnight.  A control batch was also made by 
adding PILs constituting 640 nmol DPPC (1 equivalent) to 5.8 mg EDC*MeI (19.5 mol, 30 
equivalents) and incubating 2 hours.  After incubating, 20 L 1x HBS was added and the 
preparation was incubated overnight.  Three preparations of the sample and the control were 
made.  After incubating and purifying and taking concentration measurements, the preparations 
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were diluted to 1 mg phosphorous/L and DLS measurements were taken.  Each sample was 
sampled four times for DLS measurements.  Cross-linking the polymer should increase the 
hydrodynamic radius of the liposomes because it increases the rigidity of the polymer cage 
which increases both size and drag. 
As can be seen in figure 2.4.4, the cross-linking did register substantially larger than the 
control.  Doing a t-test on the results shows p < 0.0001, indicating that there is an extremely low 
probability that the samples are the same.  Considering the increase in size was in the expected 
direction and the significance indicated by the t-test, it can be safely said that the polymer caged 
liposomes were successfully prepared. 
 
Figure  2.4.4 Polymer Caged Liposomes DLS Measurements 
100.00
102.00
104.00
106.00
108.00
110.00
112.00
114.00
PCL C PCL S
Sample
D
ia
m
et
er
 (n
m
)
 
 
 
 
 
 
 
 
 
 59 
Table  2.4.5 Polymer Caged Liposome DLS Measurements 
Sample Measurement 1 2 3 4 Mean St Dev % St Dev 
Control 1 104.15 103.13 104.77 105.03 104.27 0.84 0.81% 
Control 2 104.98 107.08 106.05 107.20 106.33 1.04 0.97% 
Control 3 107.44 105.99 106.09 103.77 105.82 1.52 1.44% 
        
Sample 1 112.16 110.67 113.24 114.06 112.53 1.47 1.30% 
Sample 2 113.85 107.53 107.18 111.42 110.00 3.21 2.92% 
Sample 3 107.87 109.26 110.65 111.77 109.89 1.69 1.54% 
 
 
Table  2.4.6 PCL DLS Summary 
Sample Mean St Dev % St Dev 
PCL C 105.47 1.40 1.33% 
PCL S 110.81 2.41 2.17% 
 
As will be discussed below ( 2.4.3.b), although the polymer caged liposomes were 
successfully prepared with the synthesized polymer and the peptide cross-linker, the resultant 
liposomes did not have any added resistance to osmotic pressure.  In order to correct this 
problem, polymer caged liposomes were also synthesized by cross-linking with ethylenediamine 
instead of the short peptide sequence.  Bare liposomes were synthesized as above (2.3.3.a) using 
27.5 mg DPPC (37.5 mol, 47.5 mol%), 3.1 mg DOPC (3.9 mol, 5.0 mol%), and 14.5 mg 
cholesterol (37.5 mol, 47.5 mol%) hydrated in 10x HBS with 100 mM carboxyfluorescein (see 
below 2.4.3.a for a discussion of the change in lipid composition).  Bare liposomes constituting 4 
mol DPPC + DOPC (1 equivalent) were added to either 25 nmol (0.006 equivalent, average 9 
nm between polymers), 53 nmol (.013 equivalents, average 6 nm between polymers), or 212 
nmol (.053 equivalents, average 3 nm between polymers) of the synthesized polymer and diluted 
to 600 L.  These were designated low (L), medium (M), or high (H) samples respectively.   
After incubating overnight to prepare polymer incorporated liposomes, EDC*MeI and 
ethylenediamine were added without a purification step (one-pot procedure) in order to increase 
 60 
yield.  To the low sample, either 146 nmol (0.036 equivalents, 50% crosslinking), 219 nmol 
(0.055 equivalents, 75% crosslinking), or 292 nmol (0.073 equivalents, 100% crosslinking) were 
added along with EDC*MeI at 1500:1 EDC:ethylenediamine.  These were designated L50, L75, 
and L100 respectively.  To the medium sample, either 313 nmol (0.078 equivalents, 50% 
crosslinking), 470 nmol (0.117 equivalents, 75% crosslinking), or 626 nmol (0.157 equivalents, 
100% crosslinking) of ethylenediamine were added along with EDC*MeI at 1500:1 
EDC:ethylenediamine.  These were designated M50, M75, and M100 respectively.  To the high 
sample either 1250 nmol (0.313 equivalents, 50% crosslinking), 1880 nmol (0.470 equivalents, 
75% crosslinking), 2500 nmol (0.626 equivalents, 100% crosslinking) of ethylenediamine were 
added along with EDC*MeI at 1500:1 EDC:ethylenediamine.  These were designated H50, H75 
and H100 respectively.   
 
Figure  2.4.5 Ethylenediamine Cross-linked PCL DLS Measurements 
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As can be seen in figure 2.4.5, each of the polymer caged liposomes showed an increase 
in average diameter verses the control (Bare Liposomes).  The values ranged from a minimum of 
+ 6.1 nm for L50, to +15.5 nm for M50.  P values were calculated for each sample verses the 
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control and the values can be seen in table 2.4.7.  All P values were less than 0.01, indicating that 
there is very little probability of any of the samples being the same as the control.  Considering 
the increase in size was in the expected direction and the significance indicated by the t-test, it 
can be safely said that the polymer caged liposomes were successfully prepared. 
 
Table  2.4.7 Ethylenediamine Cross-linked PCL DLS Measurements 
 Mean St Dev P value vs. BL 
BL 112.8 2.1 -- 
L50 118.9 1 0.0063 
L75 125.3 1.8 0.0001 
L100 122.6 1.1 0.0004 
M50 128.3 1.1 < 0.0001 
M75 126.9 4.1 0.0036 
M100 126.3 2.7 0.0002 
H50 122.9 3 0.0027 
H75 126.3 1.2 0.0001 
H100 126.7 3 0.0006 
 
Each sample was compared to other samples in its set (sets being all the L samples, M 
samples, or H samples, and then also all the 50 samples, all the 75 samples and all the 100 
samples) and p values were calculated using two sample t-tests.  The p values can be seen in 
table 2.4.8.   
With low amounts of integrated polymer (average 9 nm between polymers), adding more 
crosslinker made a significant difference in the size (although the 75% crosslinking was on the 
verge of not being significantly different from the 100% crosslinking).  With medium and high 
amounts of integrated polymer (average 6 nm and 3 nm respectively), adding different amounts 
of crosslinker made no significant difference in size.  This would indicate that at low polymer 
integration levels, the polymer probably has high mobility along the chain and can lay flat 
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against the liposome reducing added size and added drag.  Therefore, adding rigidity through 
crosslinking makes a significant difference in the measured size of the liposomes, up to the point 
where the system is 100% crosslinked.  For medium to high polymer integration levels, because 
of the close packing, the polymer probably has less mobility along the chain and cannot lay flat 
against the liposome.  Therefore, adding rigidity through crosslinking makes little difference to 
the measured size of the liposomes.  
 
Table  2.4.8 T-test P Values within Each Subgroup 
 L50 L75 L100   L50 M50 H50 
L50 * 0.0016 0.0025  L50 * <.0001 0.0647 
L75 0.0016 * 0.0507  M50 <.0001 * 0.0278 
L100 0.0025 0.0507 *  H50 0.0647 0.0278 * 
         
         
 M50 M75 M100   L75 M75 H75 
M50 * 0.5566 0.2420  L75 * 0.5143 0.3977 
M75 0.5566 * 0.8166  M75 0.5143 * 0.7927 
M100 0.2420 0.8166 *  H75 0.3977 0.7927 * 
         
         
 H50 H75 H100   L100 M100 H100 
H50 * 0.1031 0.1234  L100 * 0.0641 0.0622 
H75 0.1031 * 0.8166  M100 0.0641 * 0.8494 
H100 0.1234 0.8166 *  H100 0.0622 0.8494 * 
 
No significant trends were seen across the 50, 75, or 100% crosslinking groups.  This 
may indicate that the amount of cross linking is a larger factor in the measured size of liposomes 
than the amount of integrated polymer.  This makes sense at non-vanishingly small 
concentrations of integrated polymer.  The polymer has a certain length fully stretched and the 
liposomes have a certain radius.  At concentrations where the integrated polymer extends all the 
way around the liposome, the new radius should be the initial radius plus the length of the 
 63 
polymer.  How rigid the polymer is is going to be the main factor in how large the measured 
diameter is, so cross-linking amount ends up being more important than polymer density. 
2.4.3. Osmotic Pressure Resistance 
2.4.3.a. Initial Test 
Bare liposomes were prepared as described above (2.4.2.a) and polymer incorporated 
liposomes were prepared as described above (2.4.2.c).  Polymer caged liposomes were made by 
adding polymer incorporated liposomes constituting 640 nmol DPPC (1 equivalent) and adding it 
to 5.8 mg EDC*MeI (19.5 mol, 30 equivalents) and incubated 2 hours.  After incubating, 20 L 
of peptide crosslinker at 40 mg/mL (36 nmol, .056 equivalents, 34% crosslinking assuming 
100% reaction) was added and the preparation was incubated overnight.   
After incubating and purifying, both the sample and the control were diluted to a final 
tonicity of 5x HBS which induces 33.81 atm of osmotic pressure inside the liposomes (caused by 
the difference in tonicity of the solution trapped inside the liposome (10x) verses the tonicity of 
the of the solution outside the liposome (5x)).  The solutions were incubated overnight at 37.5 °C 
and fluorescent intensity was measured as described above (2.3.7.a) as shown in figure 2.4.6 and 
figure 2.4.7.   
Visual inspection of the samples indicated that neither the bare liposomes nor the 
polymer caged liposomes had leaked any of their contents. (Leakage and subsequent dilution of 
carboxyfluorescein (see 2.2.4.b) causes a noticeable visual change in the color of solution.  The 
concentrated carboxyfluorescein inside the liposomes is a dark red color, and at low 
concentrations of liposomes appears orange.  Upon leaking and dilution of the 
carboxyfluorescein, the solution turns bright fluorescent green.)  The initial hypothesis of this 
experiment (guided by theory from 2.1.6) was that a much smaller osmotic pressure would cause 
the bare liposomes to leak nearly all of their contents, so this result was unexpected. 
Taking the equation Pmin = (3 / R0) (R0)2/3, and average values for  (0.1 - 1 
J/m2) and  (0.02 - 0.2 nJ),1 and the radius measured above in 2.4.2.a (68.36 nm), the minimum 
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osmotic pressure needed for leaking should be as low as 0.89 atm or as high as 8.9 atm, four to 
forty times lower than the actual applied pressure.  Assuming that the values of  and  are 
closely related (being measurements of the cohesive force between the lipid molecules), to get a 
liposome at this radius that would resist over 33 atm of osmotic pressure, the values of  and  
must be raised 4 times to 4 J/m2 and 0.8 nJ, values much higher than reported average values for 
biological membranes. 
To further explore these extremely pressure resistant liposomes, the liposomes were 
diluted to a final concentration of 5x HBS and 1M Brij-58 (a strong detergent used to disrupt 
them membrane).  Visual inspection of this solution also showed no leakage of 
carboxyfluorescein from the membranes (no change from orange to green).   
A literature review of detergent resistant membranes and membrane elasticity revealed 
that detergent resistant membranes are a current research interest in membrane biology.  Of 
interest to this research is the identification that membrane rafts (which have sometimes been 
associated with detergent resistant membranes) and detergent resistant membranes often consist 
of high concentrations of saturated phospholipids and cholesterol and low concentration of 
mono- or polyunsaturated phospholipids.2,3  Also, lipid membranes made with high 
concentrations of saturated phospholipids and cholesterol and low to no unsaturated 
phospholipids have much higher elasticity constants than ovolecithin or other standard biological 
membranes that contain unsaturated and saturated phospholipids.4,5,6  Adding cholesterol greatly 
increases the membrane elasticity up to 55 mol% cholesterol in the membrane, at which point, 
the elasticity of pure cholesterol starts to decrease the elasticity of the membrane.  In fact, a 
sphingomyelin membrane with 55 mol% cholesterol can have 1.73 J/m2 elasticity constant.5  
Sphingomyelin is still monounsaturated, and saturated, long-chain phospholipids increase the 
membrane elasticity more.  A membrane that is pure DPPC + nearly 55 mol% cholesterol could 
conceivable have a membrane elasticity of 2 – 3 J/m2.  Although, this is not the 4 J/m2 needed to 
make sense of the data above, it is quite a bit closer.  Other research has shown that membranes 
made entirely out of unsaturated lipid and cholesterol will have very low water permeability.7,8  
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Increasing concentration of cholesterol in any membrane will reduce the water permeability,8 
perhaps because water permeability is closely linked to the area/lipid molecule and cholesterol 
reduces the area/lipid molecule by making the lipids pack together better.7 
Between an increase in the elasticity of the membrane caused by having solely DPPC and 
cholesterol in nearly 50 mol% each, and a decrease in the permeability of water (which will, in 
turn, decrease the effective osmotic pressure), the result above can be considered reasonable.  
Therefore, for the following tests, an unsaturated phospholipid (DOPC) was added to decrease 
the elasticity of the membrane and increase the water permeability.   
2.4.3.b. Peptide Crosslinker + DOPC 
Bare liposomes were prepared as described above (2.3.3.a) using 27.5 mg DPPC (37.5 
mol, 51.5 mol%), 2.7 mg DOPC (3.4 mol, 4.7 mol%) and 12.3 mg cholesterol (31.8 mol, 
43.8 mol%) hydrated in 10x HBS + 100 mM carboxyfluorescein.  Bare liposomes constituting 2 
mol of DPPC (1 equivalent) were added to 20 L of the prepared polymer at 200 mg/mL (4 
mg, 0.32 equivalents) and diluting to 600 L with 10x HBS.  A control batch was also made by 
adding bare liposomes constituting 2 mol of DPPC to 20L 10x HBS and diluting to 600 L 
with 10x HBS.  The integrated polymers were then crosslinked as described in the experimental 
(2.3.3.c).  PILs constituting 640 nmol DPPC + DOPC (1 equivalent) were added to 5.8 mg 
EDC*MeI (19.5 mol, 30 equivalents) and incubated 2 hours.  After incubating, 20 L of 
crosslinker at 40 mg/mL (36 nmol, .056 equivalents, 34% crosslinking assuming 100% reaction) 
was added and the preparation was incubated overnight.   
After incubating and purifying, the concentration of carboxyfluorescein in the polymer 
caged liposomes and the bare liposomes were measured as described above (2.3.6).  Both the 
sample and the control were diluted to 4 M carboxyfluorescein and a final tonicity of either 
10x, 9.75x, 9.5x, 9.25x, 9x, 8.5x, 8.25x, 8x, or 7.75x HBS (the solutions were marked by the 
difference in concentration (0, 0.25, 0.5, 0.75, 1, 1.5, 1.75, 2, and 2.25 respectively).  The 
osmotic pressure against the 10x HBS inside the liposomes can be calculated and is 0, 1.69, 3.38, 
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5.07, 6.76, 10.14, 11.83, 13.52, 15.21 atm respectively.  The solutions were incubated overnight 
at 37.5 °C and fluorescent intensity was measured as described above (2.3.7.a) as shown in 
figure 2.4.6 and figure 2.4.7.   
 
Figure  2.4.6 Fluorescent Intensity of Bare Liposomes 
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Figure  2.4.7 Fluorescent Intensity of Polymer Caged Liposomes 
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The total fluorescent intensity was scaled to a maximum of 100% and the percent release 
(which equals the scaled fluorescence values) was plotted against the osmotic pressure and the 
fitting constants were calculated (table 2.4.9, figure 2.4.8).  The difference in percent release as a 
function of pressure was calculated by subtracting the percent release curve of the bare 
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liposomes from the percent release curve of the polymer caged liposomes.  The zero value line of 
the bare liposome curve minus the bare liposome curve is also shown (figure 2.4.9).   
As can be seen in figure 2.4.8 and 2.4.9, there is very little difference in the percent 
release at any osmotic pressure between the polymer caged liposomes and the bare liposomes.  
This means that this liposome preparation is not useful for the stated goals of this project (see 
2.4.1).  Ideally a large change would be seen in the pressure resistance of the polymer caged 
liposomes that would show itself as a rightward shift in the fitting curve.  Thus at intermediate 
pressures, a substantial difference in the percent release of the carboxyfluorescein would be seen. 
 
Table  2.4.9 Fitting Constants for % Release verses Osmotic Pressure 
 BL PCL 
A 2.9171 2.6778 
B 2.8325 2.6524 
C 228.4391 228.4444 
D -0.3448 -0.5774 
E -1.4654 -0.2378 
R2 0.999989530.99999502 
 
Figure  2.4.8 Fitting Curves for Bare Liposomes and Polymer Caged Liposomes 
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Figure  2.4.9 Difference in Percent Release versus Osmotic Pressure 
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The maximum pressure the polymer cage can withstand can be estimated from the fitting 
curves (figure 2.4.8).  As explained in the literature review (2.1.6), bare liposomes should start to 
release their entrapped contents at Pmin.  Pmin can be estimated from the graph, and for most 
reliable results, the half maximum (when the carboxyfluorescein is 50% released) is the best 
point for estimating.  In the same way, the polymer caged liposomes should start to release their 
entrapped contents at Pmin + Pext, or the pressure needed to break the liposome membrane plus 
the pressure needed to overcome the polymer shell.  Again, this can be estimated from the graph 
as osmotic pressure at the half maximum of the polymer caged liposome release curve.  Pext, the 
added maximum pressure resistance from the polymer cage can be calculated by subtracting the 
osmotic pressure at half height of the bare liposome curve from the osmotic pressure at half 
height of the bare liposome curve.  For this system, the osmotic pressure at half maximum for the 
bare liposomes is 13.17 atm; the osmotic pressure at half height for the polymer caged liposomes 
is 12.16 atm.  Subtracting the two gives a maximum added pressure resistance from the polymer 
cage as -1.01 atm, or no significant added pressure resistance.   
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2.4.3.c. Ethylenediamine Crosslinker + DOPC 
To create a polymer cage that does add significant pressure resistance, it was 
hypothesized that the crosslinking needs to be tightened.  If the crosslinking is too loose, the 
polymer cage may still allow the membrane to expand past its maximum expansion point, 
allowing the liposome to release its contents before it interacts significantly with the polymer 
cage.  In order to make tighter crosslinking, a shorter crosslinker was used, namely 
ethylenediamine.   
Bare liposomes were prepared as described above (2.3.3.a) using 27.5 mg DPPC (37.5 
mol, 51.5 mol%), 2.1 mg DOPC (2.67 mol, 3.7 mol%), and 12.6 mg cholesterol (32.6 mol, 
44.8 mol%) in 10x HBS with 100 mM carboxyfluorescein.  Bare liposomes constituting 3 mol 
of DPPC (1 equivalent) were added to either 15 L (3 mg, 0.17 equivalents), 30 L (6 mg, 0.34 
equivalents), or 45 L (9 mg, 0.50 equivalents) of the prepared polymer at 200 mg/mL and 
diluting to 400 L with 10x HBS.  The resulting PILs, after incubating and purifying were added 
to either 46.5 L (700 nmol, crosslinking percent depends on sample) or 70 L (1000 nmol, 
crosslinking percent depends on sample) 1% ethylenediamine.  This gives the following samples: 
 
Table  2.4.10 Polymer Equivalents and Crosslinking in Samples 
Sample Polymer Crosslinking 
1 17% 80% 
2 17% 120% 
3 34% 40% 
4 34% 60% 
5 50% 27% 
6 50% 40% 
 
After incubating and purifying, the concentration of carboxyfluorescein in the polymer 
caged liposomes and the bare liposomes was measured as described above (2.3.6).  Both the 
sample and the control were diluted to 4 M carboxyfluorescein and a final tonicity of either 
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10x, 9.75x, 9.5x, 9x, 8.5x, 7.5x, or 5x HBS (the solutions were marked by the difference in 
concentration (0, 0.25, 0.5, 1, 1.5, 2.5, and 5 respectively).  The osmotic pressure against the 10x 
HBS inside the liposomes is 0, 1.69, 3.38, 6.76, 10.14, 16.90, and 33.81 atm respectively.  The 
solutions were incubated overnight at 37.5 °C and fluorescent intensity was measured as 
described above (2.3.7.a).    Fluorescent intensity and percent release verses osmotic pressure can 
be seen in  Appendix B.  A summary graph compiling all of the calculated curves is shown in 
figure 2.4.10.   
 
Figure  2.4.10 % Release verses Osmotic Pressure Fitting Curves 
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Table  2.4.11 Fitting Constants 
 BL 1 2 3 4 5 6 
A 11.0279 10.8532 10.9297 10.9988 10.9737 11.0182 10.9708 
B 10.8009 10.7729 10.7139 10.6431 10.6710 10.6194 10.7066 
C 236.3898 236.3994 236.3986 236.3986 236.3985 236.3987 236.3973 
D -0.0741 -0.1000 -0.0719 -0.0648 -0.0663 -0.0634 -0.0648 
E -2.6624 -0.4018 -0.5928 -0.5911 -0.6161 -0.5540 -0.8823 
R2 0.9999989 0.9999992 0.9999994 0.9999992 0.9999998 0.9999989 0.9999999 
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As can be seen in figure 2.4.10, the polymer caged curves shifted substantially to the 
right.  This indicates that the polymer cage does add substantial resistance to osmotically induced 
leakage.    Again, the amount of added resistance to pressure (PMax ext) can be estimated by 
subtracting the pressure at half maximum of the bare liposomes (PHalf Max) from the PHalf Max of 
the polymer caged liposomes.  The PMax ext and the PHalf Max are shown in table 2.4.12. 
 
Table  2.4.12 Maximum Added Pressure Resistance 
Sample PHalf Max (atm) PMax ext (atm) 
BL 5.20 0.00 
1 26.70 21.50 
2 34.25 29.05 
3 37.75 32.55 
4 36.60 31.40 
5 39.10 33.90 
6 33.40 28.20 
 
 
The PMax ext calculations represent a horizontal line across figure 2.4.10.  For this research 
though, the ‘isorelease’ lines are not nearly as important as the ‘isobaric’ lines.  This is because 
the premise of the research is that a protease can degrade the polymer shell.  When this happens, 
the osmotic pressure stays the same (isobaric) but the liposome looks more like a bare liposome 
post-degradation than the polymer caged liposome.  This means that the liposome would release 
its contents after the polymer cage has been degraded.  The isobaric difference in release 
between the bare liposomes and the polymer caged liposomes can be calculated for each sample 
by subtracting the percent release curve for bare liposomes from the percent release curve for the 
sample.  The isobaric difference curves are shown in figure 2.4.11.  The isobaric difference 
represents the maximum amount of entrapped solute that can be released by protease 
degradation, so higher values are preferential. 
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Sample 4 (0.34 equivalents polymer, 60% crosslinking) showed the greatest difference in 
% release with a maximum % release of 53.84% at 23.5 atm, although sample 5 (0.50 
equivalents polymer, 40% crosslinking) did not show a substantially large difference.  The 
smallest difference in % release was sample 1 (0.17 equivalents polymer, 80% crosslinking), 
which probably simply represents the very low amount of polymer and crosslinking. 
 
Figure  2.4.11 Differences in Percent Release versus Osmotic Pressure 
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Figure  2.4.12 Comparison to Figure 2.4.9 
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To show the increase in effectiveness of the ethylenediamine compared to the peptide 
crosslinker, figure 2.4.9 was overlaid on figure 2.4.11 and is shown in figure 2.4.12.  
Ethylenediamine as a crosslinker dramatically increased the PMax ext, lending credence to the 
theory that the earlier polymer caged liposomes with peptide crosslinker was simply not tight 
enough to keep the liposome from swelling and bursting. 
2.4.3.d. Kinetics of Liposome Swelling 
Although the swelling of the liposomes and the subsequent release of contents should be 
very fast in the presence of large osmotic pressures, this swelling and releasing is a transient state 
as discussed in 2.1.6.  This means that the liposome will swell, form pores, release some 
contents, and then the pores will seal again.  If the pressure gradient is not minimized enough to 
prevent swelling the process starts again.  Thus, even though each swelling and releasing process 
is very quick, it is conceivable that the total release of contents may happen over a much longer 
time period. 
To determine how quickly the contents of the liposomes are released in response to 
osmotic pressure bare liposomes were prepared as described above (2.3.3.a) using 27.5 mg 
DPPC (37.5 mol, 51.5 mol%), 2.1 mg DOPC (2.67 mol, 3.7 mol%), and 12.6 mg cholesterol 
(32.6 mol, 44.8 mol%) in 10x HBS with 100 mM carboxyfluorescein.  Bare liposomes 
constituting 3 mol of DPPC (1 equivalent) were added to 30 L (6 mg, 0.34 equivalents) of the 
prepared polymer at 200 mg/mL and diluting to 400 L with 10x HBS.  The resulting PILs, after 
incubating and purifying were added to 70 L 1% ethylenediamine (1000 nmol, 60% 
crosslinking).   
After incubating and purifying, the concentration of carboxyfluorescein in the polymer 
caged liposomes and the bare liposomes was measured as described above (2.3.6).  Both the 
sample and the control were diluted to 4 M carboxyfluorescein and a final tonicity of either 
10x, 9.5x, 9x, 8x, 7x, 6x or 5x HBS (the solutions were marked by the difference in 
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concentration (0, 0.5, 1, 2, 3, 4 and 5 respectively).  The osmotic pressure against the 10x HBS 
inside the liposomes is 0, 3.38, 6.76, 13.52, 20.28, 27.04 and 33.81 atm respectively.  The 
solutions were incubated at 37.5 °C and fluorescent intensity was measured at time 0 (15 min), 2 
hours, 5 hours, 24 hours, 47 hours and 71 hours as described above (2.3.7.a).    Fluorescent 
intensity and percent release verses osmotic pressure can be seen in  Appendix C.  A summary 
graph compiling all of the calculated curves is shown in figure 2.4.13 for the bare liposomes and 
2.4.14 for the polymer caged liposomes.   
 
Figure  2.4.13 Bare Liposomes % Release verses Osmotic Pressure Fitting Curves 
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Figure  2.4.14 Polymer Caged Liposomes % Release verses Osmotic Pressure Fitting Curves 
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As can be seen from figure 2.4.13, it takes more than 2 hours but less than 5 hours for the 
bare liposomes to reach osmotic equilibrium (no more increase in % release).  In figure 2.4.14, 
the polymer caged liposomes take more than 15 minutes but less than 2 hours to reach osmotic 
equilibrium.  The difference in time can be easily understood in the difference between what is 
happening to each sample.  In the bare liposomes, the osmotic pressure causes the liposome to 
swell and form pores releasing some of the contents and the pores close again.  This continues to 
happen over time, and each time it happens, the osmotic pressure goes down.  As the osmotic 
pressure goes down, the speed of pore formation also slows down.  Thus the bare liposomes will 
take some time to reach equilibrium because their progress towards equilibrium is slowed.  At 
higher pressures, the liposomes will reach equilibrium faster and at lower pressures the 
liposomes will reach equilibrium slower because of less initial rate, which can be seen in the 
curve at 2 hours.   
On the other hand, polymer caged liposomes start out the same.  They swell for a moment 
and release a little bit of their contents.  They would continue in the bare liposome trend of swell, 
pore, release, close, repeat, but they quickly expand into the polymer cage and are trapped.  Thus 
the point of equilibrium is not equalizing the osmotic pressure inside and out, but rather running 
into the polymer cage.  Since the time it takes to expand into the polymer cage is much less than 
the time it takes to release all of the contents, the polymer caged liposomes reach equilibrium 
much faster. 
The difference in percent release at each pressure at each time can be calculated again by 
subtracting the sample curve from the control curve at the same time.  Because of the difference 
in rate of how quickly the bare liposomes reach equilibrium at high and low pressures, the 
difference graph not only grows larger over time but also moves to the left (to lower osmotic 
pressures). 
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Figure  2.4.15 Differences in Percent Release versus Osmotic Pressure 
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The change in both of the variables (maximum difference in release and pressure at 
maximum difference in release) can be graphed verses time.  These are shown in figure 2.4.16 
and figure 2.4.17. 
 
Figure  2.4.16 Maximum Difference in Release verses Time 
20.00%
25.00%
30.00%
35.00%
40.00%
45.00%
50.00%
55.00%
60.00%
0 10 20 30 40 50 60 70 80 90 100
Hours
M
ax
 D
iff
er
en
ce
 %
 R
el
ea
se
 
 
 77 
Figure  2.4.17 Optimal Pressure verses Time 
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Because of the time that it takes for the liposomes to reach osmotic equilibrium, all 
further fluorescence measurements were taken at least 16 hours after starting the experiment.  
This is enough time to ensure that both the bare liposomes and the polymer caged liposomes 
have reached osmotic equilibrium but is well within the tested window for stability of results 
(results stay stable for at least three days, the maximum testing period). 
2.4.3.e. Membrane Composition 
In order to maximize the pressure resistance of the polymer caged liposomes, the next 
variable looked at was the composition of the membrane.  The membrane consists of three parts: 
DPPC which is the main lipid component of the membrane, cholesterol which is added to give 
fluidity and elasticity to the membrane, and DOPC which is added to increase water permeability 
and to prevent elasticity from becoming too large.  The DPPC is considered the main component 
of the membrane, so the other two components, DOPC and cholesterol, were changed in 
concentration to determine their effect on PMax ext. 
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Oleic Acid Content 
 To determine how oleic acid concentration affects PMax ext, bare liposomes were prepared 
as described above (2.3.3.a) using either: 
 27.5 mg DPPC (37.5 mol, 51.5 mol%), 2.1 mg DOPC (2.67 mol, 3.7 mol%), 
and 12.6 mg cholesterol (32.6 mol, 44.8 mol%)  
 28 mg DPPC (38.1 mol, 52.6 mol%), 1.4 mg DOPC (1.78 mol, 2.5 mol%) and 
12.6 mg cholesterol (44.9 mol%) 
 28.5 mg DPPC (38.8 mol, 53.7 mol%), 0.7 mg DOPC (0.89 mol, 1.2 mol%) 
and 12.6 mg cholesterol (45.1 mol%) 
in 10x HBS with 100 mM carboxyfluorescein.  Bare liposomes constituting 3 mol of 
DPPC (1 equivalent) were added to 30 L (6 mg, 0.34 equivalents) of the prepared polymer at 
200 mg/mL and diluting to 400 L with 10x HBS.  The resulting PILs, after incubating and 
purifying were added to 70 L 1% ethylenediamine (1000 nmol, 60% crosslinking).   
After incubating and purifying, the concentration of carboxyfluorescein in the polymer 
caged liposomes and the bare liposomes was measured as described above (2.3.6).  Both the 
sample and the control were diluted to 4 M carboxyfluorescein and a final tonicity of either 
10x, 9.5x, 9x, 8x, 7x, 6x or 5x HBS (the solutions were marked by the difference in 
concentration (0, 0.5, 1, 2, 3, 4 and 5 respectively).  The osmotic pressure against the 10x HBS 
inside the liposomes is 0, 3.38, 6.76, 13.52, 20.28, 27.04 and 33.81 atm respectively.  The 
solutions were incubated at 37.5 °C overnight and fluorescent intensity was measured as 
described above (2.3.7.a).    Fluorescent intensity and percent release verses osmotic pressure can 
be seen in  Appendix D.    A summary graph compiling all of the calculated curves is shown in 
figure 2.4.18 for the bare liposomes and 2.4.19 for the polymer caged liposomes. 
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Figure  2.4.18 Bare Liposomes % Release verses Osmotic Pressure Fitting Curves 
0.00000000
0.20000000
0.40000000
0.60000000
0.80000000
1.00000000
1.20000000
0 20 40 60 80 100 120
Osmotic Pressure (atm)
%
 R
el
ea
se 3.70%
2.50%
1.20%
 
 
Figure  2.4.19 Polymer Caged Liposomes % Release verses Osmotic Pressure Fitting Curves 
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As can be seen in figure 2.4.18, lower concentrations of DOPC lowered the percent 
release at lower osmotic pressures.  This is consistent with the earlier findings that DOPC is 
necessary to allow water permeability and reduce membrane elasticity.  As the amount of DOPC 
is lowered, the pressure needed to cause effective pressure in the membrane becomes larger, 
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making the lower pressures reduce their percent release.  As can be seen in figure 2.4.19, 
lowering the concentration of DOPC did not affect the percent release of the polymer caged 
liposomes significantly.  This also fits into earlier findings.  The polymer caged liposomes are 
not dependent on membrane elasticity as the main pressure resistance.  Thus, changing the 
elasticity and water permeability of the membrane does not significantly change the percent 
release. 
Because the bare liposomes have lower percent release with lower DOPC concentrations, 
the isobaric difference curves are also going to be smaller at lower DOPC concentrations, 
indicating that there is less content available for release upon protease degradation (figure 
2.4.20).  Therefore, keeping the DOPC at 3.7%, or even increasing it slightly will give the best 
results for this project. 
 
Figure  2.4.20 Differences in Percent Release versus Osmotic Pressure 
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Cholesterol Content 
To determine how cholesterol concentration affects PMax ext, bare liposomes were 
prepared as described above (2.3.3.a) using either: 
 27.5 mg DPPC (37.5 mol, 51.5 mol%), 2.1 mg DOPC (2.67 mol, 3.7 mol%), 
and 12.6 mg cholesterol (32.6 mol, 44.8 mol%)  
 27.5 mg DPPC (38.1 mol, 74.6 mol%), 2.1 mg DOPC (1.78 mol, 5.3 mol%) 
and 3.9 mg cholesterol (10.1 mol, 20.1 mol%) 
in 10x HBS with 100 mM carboxyfluorescein.  Bare liposomes constituting 3 mol of 
DPPC (1 equivalent) were added to 30 L (6 mg, 0.34 equivalents) of the prepared polymer at 
200 mg/mL and diluting to 400 L with 10x HBS.  The resulting PILs, after incubating and 
purifying were added to 70 L 1% ethylenediamine (1000 nmol, 60% crosslinking).   
After incubating and purifying, the concentration of carboxyfluorescein in the polymer 
caged liposomes and the bare liposomes was measured as described above (2.3.6).  Both the 
sample and the control were diluted to 4 M carboxyfluorescein and a final tonicity of either 
10x, 9.5x, 9x, 8x, 7x, 6x or 5x HBS (the solutions were marked by the difference in 
concentration (0, 0.5, 1, 2, 3, 4 and 5 respectively).  The osmotic pressure against the 10x HBS 
inside the liposomes is 0, 3.38, 6.76, 13.52, 20.28, 27.04 and 33.81 atm respectively.  The 
solutions were incubated at 37.5 °C overnight and fluorescent intensity was measured as 
described above (2.3.7.a).    Fluorescent intensity and percent release verses osmotic pressure can 
be seen in  Appendix E.    A summary graph compiling all of the calculated curves is shown in 
figure 2.4.21 for the bare liposomes and 2.4.22 for the polymer caged liposomes. 
Since the cholesterol level was already nearly saturated, a higher concentration of 
cholesterol was not test, only a lower concentration of cholesterol.  As can be seen in figures 
2.4.21 and 2.4.22, lowering the cholesterol level shifts PHalf Max of both the bare liposomes and 
the polymer caged liposomes to the left.  The change is approximately the same for both bare 
liposomes and polymer caged liposomes, so the PMax ext value does not change.  The optimal 
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osmotic pressure does shift to the left, though.  PHalf Max, PMax ext and optimal pressure values are 
shown in Table 2.4.13. 
 
Figure  2.4.21 Bare Liposomes % Release verses Osmotic Pressure Fitting Curves 
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Figure  2.4.22 Polymer Caged Liposomes % Release verses Osmotic Pressure Fitting Curves 
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Table  2.4.13 PHalf Max, PMax ext, and Optimal Pressure 
 20% Chol 45% Chol 
BL 6.55 20.2 
PCL 25.5 41.4 
Pmax ext 18.95 21.2 
Opt P 17.95 37.25 
 
Taking these results with the results above for differences in oleic acid concentration, the 
activities of cholesterol and oleic acid can be determined.  Oleic acid concentration affects only 
the bare liposomes and not the polymer caged liposomes.  Cholesterol concentration affects both 
bare liposomes and polymer caged liposomes.  This can be explained by oleic acid having more 
effect on the elasticity of the membrane while cholesterol has more effect on the water 
permeability of the membrane.  The elasticity of the membrane is going to affect the bare 
liposomes more than the polymer caged liposomes because the polymer caged liposomes do not 
depend on membrane elasticity to prevent release.  Rather, they depend on the ‘elasticity’ of the 
polymer cage as their main resistance to osmotic leakage.  On the other hand, water permeability 
will affect both bare liposomes and polymer caged liposome approximately the same because 
decreased water permeability reduces the effective osmotic pressure of the system.  Reducing the 
effective osmotic pressure will increase PHalf Max for both bare liposomes and polymer caged 
liposomes.   
The isobaric difference in release can also be calculated for the different cholesterol 
concentrations and is shown in figure 2.4.23.  As would be expected from the PHalf Max and     
PMax ext values, the maximum difference in release is not much different between low and high 
concentrations of cholesterol in the membrane.  The pressure at the maximum difference does 
shift to the right with increasing cholesterol concentration, though.  
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Figure  2.4.23 Differences in Percent Release versus Osmotic Pressure 
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2.4.3.f. Revisiting Polymer Content and Concentration 
In 2.4.3.c, several different polymer contents and crosslinking % were tried.  The 
polymer content tested spanned a wide range of equivalence values verses the lipid content, but 
did not span a wide range of distances between polymer molecules.  In fact, 0.017 equivalents of 
polymer equals an average of 5.3 nm between polymers in the membrane, 0.034 equivalents of 
polymer equals an average of 3.7 nm, and 0.050 equivalents of polymer equals an average of 3.1 
nm between polymers.  Since the polymer fully stretched is nearly 12 nm long, these values 
allow substantial, if not excessive overlap.  To see if a less overlapped (and thus a polymer that 
was already more stretched out) would increase the isobaric difference between bare liposomes 
and polymer caged liposomes and/or PMax ext, polymer equivalents were added to bare liposomes 
so that there would be, on average, either 3 nm, 6 nm, or 9 nm between the liposomes (increasing 
the range tested by 50%). 
Also, because the crosslinker in 2.4.3.c was chosen as an equivalent to lipid content and 
not as an equivalent to acrylic acid residue concentration, somewhat random (and sometimes 
irrational) percent crosslinking was calculated for the liposomes.  To more methodically 
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determine ideal percent crosslinking, crosslinker was chosen as an equivalent to acrylic acid 
residue content at either 25% (50% crosslinking because each crosslinker crosslinks two 
residues), 37.5% (75% crosslinking), or 50% (100% crosslinking).   
Bare liposomes were synthesized as above (2.3.3.a) using 27.5 mg DPPC (37.5 mol, 
47.5 mol%), 3.1 mg DOPC (3.9 mol, 5.0 mol%), and 14.5 mg cholesterol (37.5 mol, 47.5 
mol%) hydrated in 10x HBS with 100 mM carboxyfluorescein.  Bare liposomes constituting 4 
mold DPPC + DOPC (1 equivalent) were added to either 25 nmol (0.006 equivalent, average 9 
nm between polymers), 53 nmol (.013 equivalents, average 6 nm between polymers), or 212 
nmol (.053 equivalents, average 3 nm between polymers) of the synthesized polymer and diluted 
to 600 L.  These were designated low (L), medium (M), or high (H) samples respectively.   
After incubating overnight to prepare polymer incorporated liposomes, EDC*MeI and 
ethylenediamine were added without a purification step (one-pot procedure) in order to increase 
yield.  To the low sample, either 146 nmol (0.036 equivalents, 50% crosslinking), 219 nmol 
(0.055 equivalents, 75% crosslinking), or 292 nmol (0.073 equivalents, 100% crosslinking) were 
added along with EDC*MeI at 1500:1 EDC:ethylenediamine.  These were designated L50, L75, 
and L100 respectively.  To the medium sample, either 313 nmol (0.078 equivalents, 50% 
crosslinking), 470 nmol (0.117 equivalents, 75% crosslinking), or 626 nmol (0.157 equivalents, 
100% crosslinking) of ethylenediamine were added along with EDC*MeI at 1500:1 
EDC:ethylenediamine.  These were designated M50, M75, and M100 respectively.  To the high 
sample either 1250 nmol (0.313 equivalents, 50% crosslinking), 1880 nmol (0.470 equivalents, 
75% crosslinking), 2500 nmol (0.626 equivalents, 100% crosslinking) of ethylenediamine were 
added along with EDC*MeI at 1500:1 EDC:ethylenediamine.  These were designated H50, H75 
and H100 respectively.   
After incubating and purifying, the concentration of carboxyfluorescein in the polymer 
caged liposomes and the bare liposomes were measured as described above (2.3.6).  Both the 
sample and the control were diluted to 4 M carboxyfluorescein and a final tonicity of either 
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10x, 9.5x, 9x, 8x, 7x, 6x, 5x, 3x, 1x, or 0.5x HBS (the solutions were marked by the difference in 
concentration (0, 0.5, 1, 2, 3, 4, 5, 7, 9, and 9.5 respectively).  The osmotic pressure against the 
10x HBS inside the liposomes is 0, 3.38, 6.76, 13.52, 20.28, 27.05, 33.81, 47.33, 60.85, and 
64.23 atm respectively.  The solutions were incubated at 37.5 °C overnight and fluorescent 
intensity was measured as described above (2.3.7.a).  Fluorescent intensity and percent release 
verses osmotic pressure can be seen in  Appendix F.  A summary graph compiling all of the 
calculated curves is shown in figure 2.4.24 and the isobaric difference curves are shown in  
figure 2.4.25. 
 
Figure  2.4.24 % Release verses Osmotic Pressure Fitting Curves 
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The top six values for maximum difference in percent release verses control were all 
from samples with spacing farther apart (lower percent polymer) than 2.4.3.c.  This would 
indicate that having less overlap between the polymers is a good thing.  This is a reasonable 
result, because polymers that start out more stretched out are going to have less expansivity than 
loose polymers (and polymers that have to stretch farther to crosslink will be more stretched out).  
Thus, the membrane will expand less due to osmotic pressure before interacting with the 
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polymer cage and will thus release less of the liposomal contents in the expansion process.  The 
drawback could be a weaker polymer cage, but the data does not support this.  The lower 
polymer integration level liposomes start out at low osmotic pressures with lower leakage and 
continue to be lower when the osmotic pressure is raised.  There does seem to be a drop off in 
polymer cage strength in the very low integration levels (spacing average 9 nm apart). 
   
Table  2.4.14 PHalf Max and PMax ext Values 
 PHalf Max PMax ext 
Area under 
Difference Curve 
BL 27.3 0 0 
L50 49.25 21.95 393 
L75 39.5 12.2 222 
L100 45.35 18.05 331 
M50 42.1 14.8 282 
M75 53.2 25.9 451 
M100 52.55 25.25 441 
H50 21.65 -5.65 -68 
H70 17.85 -9.45 -48 
H100 18.15 -9.15 -90 
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Figure  2.4.25 Differences in Percent Release versus Osmotic Pressure 
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The very high concentration of polymer (average spacing 3 nm apart) actually shows 
very little difference from bare liposomes.  This is probably due to a very large expansivity of the 
polymer cage before it will resist osmotic pressure.  Although the polymer cage is well 
crosslinked, since the polymer is very close together, it can be stretched apart a little bit before 
the crosslinking is truly tight.  In very high concentrations of polymer, the expansivity appears to 
be greater than the maximum membrane expansivity, so the liposomes will leak out all of their 
contents before the polymer shell will provide resistance to osmotic pressure.   
Thus, the optimal spacing between polymers appears to be between 5 and 6 nm on 
average (1.3% - 1.9% polymer).  These values of polymer integration have consistently had the 
highest isobaric pressure differences and the highest PMax ext values.  The optimal value of 
crosslinking seems to depend strongly on polymer integration level.  At higher integrations, less 
crosslinking seems to be preferred, while at lower integrations, more crosslinking seems to be 
preferred.   
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2.4.4. Urokinase Release of Contents 
Initial Test 
Bare liposomes were prepared as described above (2.3.3.a) using 27.5 mg DPPC (37.5 
mol, 51.5 mol%), 2.1 mg DOPC (2.67 mol, 3.7 mol%), and 12.6 mg cholesterol (32.6 mol, 
44.8 mol%) in 4.75x HBS with 100 mM carboxyfluorescein.  Bare liposomes constituting 3 
mol of DPPC (1 equivalent) were added to 30 L (6 mg, 0.34 equivalents) of the prepared 
polymer at 200 mg/mL and diluting to 400 L with 4.75x HBS.  The resulting PILs, after 
incubating and purifying were added to 70 L 1% ethylenediamine (1000 nmol, 40% 
crosslinking).  This is the same as sample 4 from 2.4.3.c except in 4.75x HBS instead of 10x 
HBS.  It was prepared in 4.75x HBS so that when diluted into 1x HBS (for uPA studies) they 
would be at the optimal pressure for maximum difference in percent release calculated above. 
After incubating and purifying, the concentration of carboxyfluorescein in the polymer 
caged liposomes was measured as described above (2.3.6).  The liposomes were diluted to 4 M 
carboxyfluorescein and a final tonicity of 4.75x HBS and the sample had either no uPA added or 
25 g/mL uPA added.  The osmotic pressure against the 4.75x HBS inside the liposomes is 25 
atm, the optimal pressure for maximum difference in 2.4.3.c.  The solutions were incubated 
overnight at 37.5 °C and fluorescent intensity was measured as described above (2.3.7.a).    
Fluorescent intensity can be seen in  Appendix G. A summary graph showing average total 
fluorescent intensity is shown in figure 2.4.26.   
 
Figure  2.4.26 Total Fluorescent Intensity 
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As can be seen in figure 2.4.26, there was very little difference between the no uPA 
sample and the uPA sample, indicating that the polymer caged liposome is not sensitive to uPA 
as was desired.  The p value between the two samples was 0.5173, again indicating that there is 
no difference between the samples.  There are three instantly obvious reasons why this could be 
happening: 1) the liposomes are not sensitive to uPA and the experiment failed; 2) there is not 
enough uPA to effectively degrade the polymer cage; or 3) the uPA that was used was not active 
for some reason.  Of these three possibilities, #2 can be discounted immediately because 25 
g/mL is a very high concentration relative to biological systems, so needing a higher 
concentration that 25 g/mL would be impractical for the desired effects.  Of the remaining two 
possibilities, #3 is by far the easiest to fix.  Therefore a fresh batch of uPA was ordered. 
Second Test 
While waiting for the new uPA to arrive, the polymer caged liposomes were optimized as 
described above.  Once the uPA arrived, bare liposomes were synthesized as above (2.3.3.a) 
using 27.5 mg DPPC (37.5 mol, 47.5 mol%), 3.1 mg DOPC (3.9 mol, 5.0 mol%), and 14.5 mg 
cholesterol (37.5 mol, 47.5 mol%) hydrated in 8x HBS with 100 mM carboxyfluorescein.  Bare 
liposomes constituting 4 mold DPPC + DOPC (1 equivalent) were added to 53 nmol (.013 
equivalents, average 6 nm between polymers)) of the synthesized polymer and diluted to 600 L.     
After incubating overnight to prepare polymer incorporated liposomes, EDC*MeI and 
ethylenediamine were added without a purification step (one-pot procedure) in order to increase 
yield.  To the PILs 470 nmol (0.117 equivalents, 75% crosslinking) of ethylenediamine were 
added along with EDC*MeI at 1500:1 EDC:ethylenediamine.   
After incubating and purifying, the concentration of carboxyfluorescein in the polymer 
caged liposomes and the bare liposomes were measured as described above (2.3.6).  Both the 
bare liposomes and polymer caged liposomes were diluted to 4 M carboxyfluorescein and a 
final tonicity of 1x HBS without uPA (for a positive and negative control).  The polymer caged 
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liposomes were also diluted to 4 M carboxyfluorescein and a final tonicity of 1x HBS with 25 
g/mL uPA (as the sample).  Finally, the polymer caged liposomes were also diluted to 4 M 
carboxyfluorescein and a final tonicity of 8x HBS without uPA (as a baseline value). The 
osmotic pressure in 1x HBS against the 8x HBS inside the liposomes is 47.33 atm (8x verses 8x 
is 0 atm).  The solutions were incubated at 37.5 °C overnight and fluorescent intensity was 
measured as described above (2.3.7.a).  Fluorescent intensity can be seen in  Appendix H.  A 
summary graph showing average total fluorescent intensity is shown in figure 2.4.27.  T-test P 
values for each comparison are given in table 2.4.15 
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Table  2.4.15 T-test P Values 
t test Base vs. - uPA Base vs. + uPA - uPA vs. + uPA Base vs. BL - uPA vs. BL + uPA vs. BL 
p value <.0001 0.0001 0.6617 0.0001 0.0009 0.0009 
Significant Yes Yes No Yes Yes Yes 
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As expected, the – uPA value was somewhat above baseline, indicating a small amount 
of leakage with osmotic stress but significantly lower than the BL at the same osmotic pressure.  
The most important result is the comparison of the + uPA and – uPA samples.  They show very 
little difference in total intensity and the p value is 0.6617 between the two, indicating that they 
are not different.  Thus, the polymer caged liposomes are still not sensitive to uPA and the new 
uPA did not solve the problem. 
Third Test 
The last possible option, barring the experiment having failed, is that there was nothing 
wrong with the uPA of either batch, except that it had become denatured during storage.  To test 
this last possibility, the same liposomes were prepared as in the second test above.  The same 
fluorescent test samples were prepared as well, with the exception of the baseline sample (which 
was considered unnecessary).  Thus there is a – uPA sample as a negative control, a BL sample 
as a positive control, and a + uPA sample as the test sample.  A fourth sample was also 
introduced that had renatured uPA in it.  A sample of uPA was renatured by heating to 90°C for 
5 minutes and then cooling to room temperature and repeating twice.  This sample of uPA was 
also used to make a + uPA sample, so that there are two +uPA samples one with non-renatured 
uPA and one with renatured uPA.  Fluorescent intensities can be seen in figure 2.4.28 and a 
summary graph of total fluorescent intensity can be seen in figure 2.4.29 and a table of p values 
can be seen in table 2.4.16. 
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Figure  2.4.28 Fluorescent Intensity 
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Figure  2.4.29 Total Fluorescent Intensity 
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Table  2.4.16 T Test P Values 
t test No uPA / uPA No uPA / uPA RN uPA / uPA RN uPA RN / BL uPA / BL No uPA / BL 
p value 0.3426 0.0071 0.0203 0.0888 0.0032 0.0093 
Significant No Yes Yes No Yes Yes 
 
As can be seen in figure 2.4.29, there is a difference between the uPA and uPA renatured 
sample, which would indicate that the uPA that was used before was denatured.  More 
importantly, there is a difference between the no uPA sample and the uPA sample with the uPA 
sample being significantly higher (p value 0.0071).  Compared to the BL sample, the uPA RN 
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mean is lower, but it is on the verge of not being statistically significant (p value 0.0888) 
indicating there is a small possibility that the uPA RN and the BL are the same.  Whether it is the 
same or not, though, the polymer caged liposomes are sensitive to the renatured uPA and release 
their contents in response to uPA.  This concludes the last necessary step in proving that the 
polymer caged liposomes are a valid possibility for protease sensitive treatments. 
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2.5. Conclusion 
2.5.1. Summary 
The purpose of this study was to develop a drug delivery device that would quickly 
release its contents upon interaction with a specific protease, but would be stable until then.  The 
proposed method (figure 2.5.1) was to prepare liposomes in a high tonic buffer so that they are 
intrinsically unstable in low tonic buffers.  The intrinsically unstable liposomes would then be 
stabilized by forming a covalently bound polymer cage around the liposome.  This would be 
done by synthesizing a cholesterol anchored protease sensitive block copolymer and then 
allowing the cholesterol anchor to diffuse into the membrane of the bare liposomes.  The 
integrated polymer would then be crosslinked with a diamine (since one of the blocks of the 
polymer is acrylic acid, a diamine will crosslink the polymer) to give polymer caged liposomes. 
 
Figure  2.5.1 Proposed Method for Developing a Protease Sensitive Drug Delivery System 
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Each of these steps has been successfully accomplished.  A cholesterol-anchored, 
protease-sensitive, block copolymer containing polyacrylic acid was synthesized (2.3.2).  Bare 
liposomes were successfully prepared in high tonic buffer (2.4.2.a) and the synthesized polymer 
was successfully integrated into them (2.4.2.c).  The polyacrylic acid in the polymer was 
successfully crosslinked with both a short peptide sequence containing a lysine to make a 
diamine and ethylenediamine (2.4.2.d).   
 
 
Figure  2.5.2 Proposed Method for Releasing the Contents of the Polymer Caged Liposomes 
   
The proposed method of release was by protease degradation of the polymer.  This was 
accomplished by incorporating a peptide sequence containing the consensus sequence for uPA as 
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one of the blocks of the synthesized copolymer (2.3.2).  The polymer cage was shown to confer 
substantial osmotic pressure resistance (2.4.3) and the factors affecting how much pressure 
resistance the polymer cage confers were studied.  It was then shown that uPA can degrade the 
polymer cage and release the contents of the polymer caged liposomes (2.4.4).   
As mentioned above (2.4.1), to provide proof of concept of the protease sensitive 
polymer caged liposome as a usable drug delivery system, the following needs to be proved: 
1. Bare liposomes must be successfully prepared 
2. Polymer incorporated liposomes must be successfully prepared 
3. Polymer caged (crosslinked) liposomes must be successfully prepared 
4. Polymer caged liposomes must show significant resistance to osmotic pressure 
induced leakage verses bare liposomes 
5. Polymer caged liposomes must show significant increase in percent release when 
exposed to urokinase plasminogen activator 
6. Each of these steps has been accomplished, so, as a proof of concept, this is a 
workable system. 
Quod erat demonstrandum 
2.5.2. Protease Sensitive Liposome Potential and Significance 
The system demonstrated above holds enormous potential as a drug delivery system for 
cancer therapy and perhaps many other diseases as well (as long as there are specific proteases 
associated with the disease, such as Alzheimer’s disease).  Liposomes already have some 
selectivity towards cancer (2.1.4) because of the EPR effect.  Adding sensitivity to cancer 
associated proteases can increase the specificity of the liposome as a drug delivery device, 
minimizing unwanted side effects from general delivery and increasing the drug delivery to the 
site (figure 2.5.3).  This system could also be stacked to provide multiple layers of specificity by 
making liposomes sensitive to different proteases.  By filling one liposome with a prodrug and 
another liposome with an activator, three levels of specificity can be obtained (figure 2.5.4). 
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Figure  2.5.3 A schematic showing how protease sensitive liposomes would target cancer.  
This system would have two levels of specificity: the EPR effect and sensitivity to uPA. 
     
 
 
Figure  2.5.4 A schematic showing how protease sensitive polymers could be stacked to 
provide extra specificity.  This system would have three layers of specificity: the EPR 
effect, sensitivity to uPA and sensitivity to MMT-1. 
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A major reason cancer therapy sometimes fails is that the undesired side effects of the 
drug limit the amount of the drug that can be delivered systemically and thus the amount of drug 
that can be delivered to the tumor.  A more specific method of delivery could decrease systemic 
delivery (and thus unwanted side effects) and increase tumor delivery (increasing effectiveness 
of the drug).  Thus the cancer therapy would be much less likely to fail because of low dosages 
or stopped because of overwhelming side effects.   
2.5.3. Future Work 
As a proof of concept study, much more work needs to be done to make the protease 
sensitive liposomes a useable system.  As a next step, three things are proposed: 1) synthesize a 
block-copolymer with an embedded consensus sequence for another cancer associated protease 
and use this to make protease sensitive liposomes to a different protease; 2) test the protease 
sensitive liposome on cell lines known to express the desired cancer associated protease and on 
cell lines known not to express the desired cancer associated protease; and 3) test the liposomes 
in small animals for biosystem compatibility and effectiveness as a treatment for cancer. 
To provide a layered system such as the one shown in figure 2.5.4, multiple different 
protease sensitive liposomes need to be developed to target different proteases.  Also, not all 
cancers express uPA so other protease targets would expand the range of cancers that the single 
layer treatment would be useful for as well.  So, the first proposal is to develop another protease 
sensitive liposome to a different cancer associated protease by going through the procedure 
detailed above with a different consensus sequence.  As a list of consensus sequences is already 
known (table 1.3.1), the procedure for synthesizing the cholesterol-anchored block copolymer is 
already optimized and the procedures for preparing and testing the protease sensitive liposomes 
have already been developed, many new consensus sequences could be tested in a relatively 
short period of time.   
Although the uPA sensitive liposomes worked in a test tube, biological systems often 
produce unexpected results.  Thus the second proposal is to test the liposomes against a range of 
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cells expressing different proteases in vitro.  This will show that the liposome system is stable 
under biological conditions, is effective against biological concentrations of uPA (or other 
proteases), and resists other proteases that it is not targeted against.  Also, how the drug is 
delivered could also be determined, whether it is simply releasing the drug in the extracellular 
matrix upon coming in contact with the protease or if it is fusing with the membrane (see 2.1.7). 
The third proposal, to test the liposomes in vivo, will demonstrate that the liposomes are 
stable in the blood and can be delivered to the cancer site.  It will also demonstrate that the 
polymer shell does not produce unwanted side effects in the body.  The third proposal will also 
test the true effectiveness of the drug delivery system in cancer therapy.  By testing in mice (or 
other small animals) with known tumors, the liposomes, containing a cancer therapy drug, can be 
tested for their ability to slow, stop, or reverse the growth of the tumor.  This would be the end 
goal of this project, a drug delivery system that is effective at delivering therapeutic (toxic) 
agents to tumors that reduces or eliminates the tumor.   
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3. Protease Sensitive Pro-MspA 
3.1. Literature Review 
3.1.1. The Complement System 
The complement system is a subset of the innate immune system that was discovered in 
1896 by Jules Bordet.  Bordet demonstrated that there were two components of blood serum that 
were responsible for its antibacterial properties.  When heated, blood serum looses its 
antibacterial properties.  Bordet demonstrated that this was only due to the loss of activity of one 
of the components by heating blood serum and then adding fresh serum that had the antibodies 
removed.  The antibody depleted serum by itself was not able to lyse cells, nor was the heated 
serum, but together, the activity was restored.  Bordet concluded that the first component of 
blood serum was the antibodies, and these were resistant to heat.  The second component of 
blood serum was heat labile, and must be added back in after heating for blood serum to retain its 
antibacterial properties.  Several years later, Paul Ehrlich designated the system “complement” 
because it complemented the activity of the antibodies in blood serum.1 
The complement system makes up nearly 5% of the protein content in blood serum.  
There are fourteen known components in the complement system, and most of these components 
are proenzymes that have no activity until a trigger (such as an activated antibody complex) 
causes the complement cascade.  In the cascade (Figure  3.1.1), either C1, C3 or MASP 1 + 2, are 
activated from a proenzyme to an active protease (either by self-cleavage, or association).  Then 
C1 or MASP 1 + 2 cleave C2 and C4, which bind together and form another protease (C3 
associates with Factor B, which is cleaved by Factor D to become an active protease), called C3 
convertase.  C3 convertase cleaves C3 which causes it to bind to C3 convertase changing it to C5 
convertase another active protease.  C5 convertase binds C5 and cleaves it, producing C5a and 
C5b.  C5b can recruit C6, C7, C8 and multiple units of C9 to form the membrane attack 
complex.1 
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Figure  3.1.1 The Complement Cascade 
 
The main effecter of the complement cascade is the membrane attack complex.  C5 when 
it is cleaved forms a C5a and C5b fragment.  The C5a fragment simply diffuses away, but the 
C5b complex binds to the surface of the offending membrane.  C6 binds to C5b on the surface to 
stabilize C5b (which otherwise would become inactive in less than two minutes).  C7 then binds 
to C5b6 and causes a change in the C5b67 complex that exposes a hydrophobic region to make 
the C5b67 complex ampiphilic allowing it to insert into the membrane.  C8 then binds to the 
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C5b67 complex and also undergoes a hydrophilic-ampiphilic transition which causes a small 
pore to form in the membrane (~1 nm).  C5b678 then recruits up to 17 C9 proteins to form the 
membrane attack complex.  The C9 proteins form a much larger pore in the membrane (~10 nm) 
and is much more damaging to the cell (Figure  3.1.2, Figure  3.1.3).1   
 
 
Figure  3.1.2 A photomicrograph of the membrane attack complex 
 
 
Figure  3.1.3 A photomicrograph of the MAC forming pores in a membrane 
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The pore formed by the membrane attack complex (MAC), disrupts the finely balanced 
ion concentrations on both sides of the membrane.  Sodium ions rush into the cell, while 
potassium and chloride ions flow out of the cell.  The net results is an influx of ions into the cell, 
which causes osmosis as water follows the sodium ions into the cell (Figure  3.1.4).  The osmotic 
pressure causes the cell membrane to swell and burst, killing the cell.1   
 
 
Figure  3.1.4 A schematic of the membrane attack complex showing it poking holes in the 
membrane.  The careful balance of ions across the membrane is destroyed. 
 
The complement system is very finely tuned to kill unwanted cells, and there is very little 
defense the attacked cell can offer once the membrane attack complex has been formed.  Thus 
the complement system, or a similar system would be an ideal cancer therapy treatment.  In fact, 
several systems have tried to exploit the complement system and activate it to kill cancer cells.  
For example, antibody treatments, such as trastuzumab and rituximab have had their Fc portions 
modified to increase complement activation and BCG has been applied to tumors of the walls of 
the urinary bladder (to induce complement activation) with some success.  In most cases, though, 
cancer cells seem immune to complement and complement activation may, in fact, increase 
tumor growth.2, 3 
Recently, several researchers have shown that cancerous cells often over express 
complement regulators such as CD46, CD55, and CD59.3, 4  These regulators inhibit the 
formation of the MAC, and prevent complement from having a cytotoxic effect on the cancer 
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cell.  CD46, CD55 and CD59 do not prevent the initial cascade of complement from happening, 
so activated C5b is often formed at cancer sites.  C5b can cause the MAC to form on almost any 
membrane, and as such, it is often used as a damper to the immune system to keep it from 
jumping into hyperdrive and killing by hypercytokinemia.  When a lot of MAC forms, it can lyse 
immune effector cells as well as the invading cells, thus providing a negative feedback loop and 
preventing the positive feedback loop of hypercytokinemia from killing the organism.  Cancer 
exploits this negative feedback loop.  Since cancer does not downregulate C5b production, only 
its effectiveness against the cancerous cells, cancer effectively nullifies the complement system 
and dampens the entire immune system response by causing lysis of other effector cells.3 
Thus, complement would be a very good system to exploit for treating cancer, except 
cancer has already exploited it in the other direction.  If a system similar to complement could be 
developed that would lyse the cancer cells by forming pores in the membrane without being 
subject to down regulation by complement regulators, it would make an excellent candidate for 
cancer therapy.   
3.1.2. MspA 
A possible MAC imitator is Mycobacterium smegmatis porin A (MspA).  MspA is a 
porin isolated from Mycobacterium smegmatis a member of the mycobacterium genus, the most 
famous of which is M. tuberculosis, which, along with many other of the genus members, causes 
tuberculosis.  Mycobacterium are somewhat of an oddity in the microbiology world.  One of 
their best known oddities is their cell membrane and cell wall.  Most bacteria have an inner cell 
membrane and an outer cell membrane of about the same size (roughly 6 nm), with a free 
peptidoglycan layer in between (Figure  3.1.5). Mycobacteria, on the other hand have a much 
larger outer membrane (~10 nm) that is covalently linked to the peptidoglycan layer underneath 
(Figure  3.1.6).  The large size of the outer membrane is caused by mycolic acids, extremely long 
chain lipids synthesized by mycobacteria.  This outer membrane makes mycobacteria notoriously 
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resistant to many standard antibiotics because of low diffusion through the large membrane and 
lack of free access to the peptidoglycan layer.5,6,7   
 
 
Figure  3.1.5 The membrane of e coli as a representative bacterial membrane. 
 
 
Figure  3.1.6 A membrane from m. tuberculosis as a representative mycobaterial membrane 
 
 107 
As mycobacteria have very different outer membranes from other bacteria, it would be 
expected that the pores that are in the outer membranes would also be quite different.  Standard 
bacterial porins are trimeric structures that form three pores in the membrane and are 
approximately 6 nm tall (Figure  3.1.7).8   
 
Figure  3.1.7 A sucrose specific porin from Salmonella typhimurium as a representative 
bacterial porin. 
 
Figure  3.1.8 MspA.  Green indicates hydrophilic residues, yellow hydrophobic residues. 
(dimensions are in Angstroms) 
 
Several porins have been isolated from M. smegmatis that are all fairly similar.  The most 
prevalent was named Mycobacterium smegmatis porin A (Figure  3.1.8).  X-ray crystal studies 
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revealed that MspA is a homooctameric porin that forms a single pore in the membrane and is 
nearly 10 nm tall. MspA is an incredibly stable protein and resists denaturing even in conditions 
such as 100°C with 3% SDS.  This stability allows it to be separated from the membrane and 
purified without denaturing it.9 
MspA has several similarities to the MAC.  It is multimeric protein that forms pores in 
membranes.  It has a very hydrophobic region that desires to be buried in the hydrophobic 
membrane, and the energetics of burying the MspA should be strong enough to form pores in the 
membrane.  It is also different in many ways.  It should not interact with the complement 
regulatory proteins.  It is very stable and should be able to be transported through the body (as 
opposed to formed on the spot).  It does not exist as a pro-porin.  If MspA is able to poke holes in 
membranes, there is no regulation on which membranes it will poke through. 
Because of these similarities and differences, MspA makes a good candidate for a MAC 
replacement for use in cancer therapy.  To be a good cancer therapy candidate it will need to be 
proven that: 1) MspA can poke holes in membranes; 2) the magnitude and multitude of these 
holes is enough to induce cell lysis or apoptosis; and 3) MspA can be modified somehow to 
select cancerous cells from non-cancerous cells. 
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3.2. Experimental 
3.2.1. Materials 
MspA and MspA A96C were obtained from the Michael Niederweis lab at University of 
Alabama Birmingham.  MDA 231 and MatBIII cell lines were obtained from ATCC and were 
cultured in recommended media.  The peptide (SRSRSRSRSRSGRSAGGGC) was purchased 
from GenScript (Piscataway, NJ).  All other materials were obtained from Fisher Scientific.   
3.2.2. Atomic Force Microscopy 
Mica plates were cut into 1 cm2 squares and cleaved by slowly removing the top layer of 
mica to expose a clean and microscopically smooth mica surface.  The sample to be imaged was 
added to the mica plate and dried overnight.  The sample was then imaged using a PicoScan 
AFM in MACmode (magnetic alternating current mode, similar to tapping mode (AC mode) but 
typically with less force applied on the sample) using a fresh MACmode tip stored under argon 
(to prevent oxidative destruction of the magnetic coating).  Images were collected and analyzed 
with the PicoScan software.   
3.2.3. Cell Assays  
Cell lines were obtained from ATCC and were continually passaged in the recommended 
media in T75 flasks.  To start a test, cells that were ready to passage were passaged into 12 well 
flat-bottom plates and allowed to come to 75% confluence.  Testing conditions were then added.  
Post-testing conditions, the cells were counted using a hemocytometer.  The cells were washed in 
PBS and then lifted by adding 100 L trypsin and rocking for two minutes or until cells were 
visibly detached.  100 L of media was then added to quench the trypsin activity and an equal 
volume of 0.4% trypan blue in PBS was added to stain non-viable cells.  After staining, the cells 
were diluted until less than 100 but more than 50 cells were counted in the hemocytometer.  The 
cells were then counted in the hemocytometer (discounting stained cells) and the counts were 
used to calculate total cells in the well.   
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3.2.4. Synthesis of Pro-MspA 
MspA A96C was obtained from the Niederweis group at UAB at 60 g/mL (37.5 M) 
and the peptide SRSRSRSRSRSGRSAGGGC was obtained from GenScript and diluted to 2 
mM.  To reduce any currently existing cys-cys bonds, 15 L of 120 M DTT (1.5 eq.) was 
added to 400 L of MspA (1 eq.).  Separately, 150 L of 120 M DTT (15 eq.) was added to 6 
L of the peptide (10 eq.).  Both reactions were incubated overnight at room temperature.  The 
next day, both reactions were mixed together (1 eq. MspA, 10 eq. peptide, 1.25 eq. 
peptide/MspA cysteine) and 27.5 L of 1.10 M NaOH and 150 L of 132 M Chloramine-t (88 
equivalents) was added to the reaction mixture to oxidize the cysteine-cysteine bonds.  Reactants 
and side-products (peptide-peptide cysteine bonds) were removed by adding 9 mL 1x PBS and 
ultrafiltrating using filters with MWCO of 15 kDa to 0.75 mL.  The product was washed twice 
more using 9 mL 1x PBS and ultrafitered to 0.75 mL.  
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3.3. Results and Discussion 
3.3.1. AFM Studies 
Initially, it was desired to note the similarity between MspA and the MAC by getting 
high resolution images of the MspA pore and comparing them to the MAC complex.  To do this, 
MspA stock (3 M) was diluted to 3 nM using water/methanol (80%/20%).  A 150 L drop was  
 
 
Figure  3.3.1 AFM image of MspA on mica. 
 
put on a 1 cm2 piece of cleaved mica and dried at 37.5°C overnight.  The mica was then imaged 
using a PicoScan AFM in MACmode.  As can be seen in Figure  3.3.1, MspA is stable enough to 
image, and the pore structure shows up clearly in AFM.  The dimensions measured match 
closely the X-ray measurements (10nm x 10 nm x 10 nm).  Comparing to Figure  3.1.2 shows that 
MspA has a very similar shape the MAC.   
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3.3.2. Membrane Insertion Studies 
To prove that MspA could integrate into membranes, another AFM study was set up.  A 
poly-N-isopropyl-amine (pNIPAM) synthetic membrane was prepared on cleaved mica by 
making a solution of 50 mg/mL pNIPAM in acetonitrile/water (50%/50%).  A 50 uL drop of the 
pNIPAM solution was then dropped onto the center of the cleaved mica piece, and the mica was  
 
 
Figure  3.3.2 AFM image of MspA integrated into the pNIPAM membrane 
 
spun at 3000 RPM for 45 seconds on an industrial spin coater to prepare a membrane that was 
approximately 5 nm thick.  The membrane was dried at 37.5°C overnight and then 150 uL of 3 
nM was dropped on to the membrane and left for one hour.  The mica was then washed with 
distilled water to remove unbound MspA and dried at 37.5°C overnight.  The mica was then 
imaged using a PicoScan AFM in MACmode.   
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As can be seen in Figure  3.3.2, the MspA does integrate into the membrane.  There is an 
abundance of protein in the image, although the resolution is not excellent (‘soft’ samples such 
as pNIPAM drastically reduce the maximum resolution in AFM due to the force of the tip 
interacting with the sample).  The porin with the best resolution was enlarged and is seen to the 
right.  The pore structure is still evident, showing that the MspA retained its native conformation 
upon entering the membrane.  Also, in the cross section view, the MspA is now only 5 nm tall, as 
opposed to 10 nm in Figure  3.3.1.  This would indicate that the MspA is actually buried in the 
membrane (which is ~5 nm thick) and has inserted itself and is not merely interacting with the 
surface of the membrane as half of the height is below the surface of the membrane and is not 
imaged.   
3.3.3. Cell Toxicity 
Since AFM results indicate that the MspA can integrate into membranes and form pores, 
the toxicity of MspA against cultured cells was tested next.  MDA231 cells (human metastatic 
breast cancer cell line), were cultured to 75% confluency in 12 well flat-bottom plates containing 
1 mL of media.  MspA was diluted to various concentrations in 1x PBS and added to the media.  
The cells were placed in the incubator for 36 hours and then live cell counts were taken.  As can 
be seen in Figure  3.3.3 and Figure  3.3.4, MspA is extremely cytotoxic, with 100% cell death at 
approximately 2.5 nM.  This is consistent with MspA acting similarly to the MAC.  Not very 
many holes need to be poked in a membrane before the cell cannot compensate, so the toxicity of 
a pore forming toxin is quite high. 
 
 
 
 
 
 
 114 
Figure  3.3.3 % Live Cells vs. [MspA] 
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Figure  3.3.4 % Live Cells vs. log[MspA] 
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3.3.4. Mechanism of Toxicity 
Once it was established that MspA was extremely cytotoxic, the mechanism of toxicity 
was looked into.  The hypothesis was that MspA is a pore forming toxin similar to the MAC.  If 
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MspA does form pores in the membrane, an excellent method of proving this would be to watch 
molecules that normally are excluded by live cells enter the cells.     
3.3.4.a. Chromophore/Fluorophore Exclusion 
To test increased membrane permeability post-MspA treatment, cells were cultured to 
75% confluency in 12 well plates.  Either 100 L of MspA in PBS (for a final concentration of 
0.4 nM, chosen to create some pores in the membrane without a large population of cell death), 
or 100 L of PBS (no MspA) was added to the cells and the cells were incubated two hours.  
Then various dyes were added to both the sample (with MspA) and the control (without MspA) 
wells in 100 L for a final concentration of 0.2% wt/vol dye.  The cells were incubated one more 
hour and then were observed in the microscope or fluorescent microscope.  For a successful test, 
the cells with MspA added should be stained, while those without MspA should not be stained.  
If both sets of cells are stained, it would indicate that the dye can cross the membrane readily, 
and is not useful for this study.  If neither set of cells are stained, it could indicate one of two 
things: 1) MspA does not form pores in the membrane; or 2) the dye is too large to go through 
the pore formed by MspA. 
The dyes tested include azo blue, trypan blue, trypan blue + MgSO4, propidium iodide, 
ethylene bromide, and DAPI.  None of these dyes produced a positive result (the MspA 
containing cells stained while the non-MspA cells unstained).  Some stained all of the cells (azo 
blue, ethylene bromide, DAPI) and some stained none of the cells (trypan blue, trypan blue + 
MgSO4, propidium iodide).  As stated above, this could mean that either MspA does not kill cells 
by forming pores, or that the pore of MspA is too small to fit conventional dyes through.   
3.3.4.b. Current Induction 
To differentiate between the two possibilities above, other evidence of MspA forming 
pores in membrane was looked for.  The first evidence is already detailed above in  3.3.2, 
demonstrating the MspA can enter the membrane and form pore-like structures in it.  Also, from 
x-ray studies, it is known that the constriction zone of MspA is less than 1 nm in diameter and it 
 116 
is defined by sixteen aspartate residues giving it a very negative charge.1  The small size and 
large negative charge of the constriction zone would likely repulse most biological dyes. 
The final piece of evidence was provided by the Niederweis group at UAB who were 
studying the effect of deleting residues from the periplasmic loop of MspA.2  As part of this 
study, they tested the transmembrane conductance of a diphytanoylphosphatidylcholine 
membrane after adding MspA.  Without any pores, the membrane blocks virtually all current 
flow, making the conductance zero.  If MspA forms true pores in the membrane, the 
transmembrane conductance will increase because electrolytes are able to cross the membrane to 
connect the electrodes. 
The channel activity of the protein was measured by preparing a 
diphytanoylphosphatidylcholine membrane across a pore that connected an aqueous circuit 
(containing 1 M KCl as the electrolyte).  A voltage of -10 mV was applied to the circuit.  0.02 ng 
of freshly reconstituted MspA pores were added to both the cis and trans sides of the membrane 
and conductance was recorded against time. 
 
 
Figure  3.3.5 Conductance versus time. 
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As can be seen in Figure  3.3.5, addition of MspA caused discreet jumps in the 
transmembrane conductance.  This would indicate that MspA does form true pores in the 
membrane that allow the KCl to pass through the membrane connecting the circuit.  Thus, the 
hypothesis that MspA does not cause toxicity by pore formation was rejected. 
3.3.5. Toxicity and Selectivity of Pro-MspA 
Since MspA has been shown to be a suitable imitator of the MAC complex, to make a 
good cancer treatment, MspA’s pore formation must be triggered by the cancer and not 
elsewhere.  An obvious method for preventing MspA pore formation would be to simply 
preventing it from inserting into the membrane.  As can be seen above (Figure  3.1.8), the lower 
half of MspA is very hydrophobic, which is what drives it insertion into the membrane.  The 
upper half, on the other hand, is mixed hydrophobic and hydrophilic and will not insert nearly as 
readily as the lower half.  Thus, to prevent insertion, the hydrophobicity of the lower half needs 
to be masked somehow.   
To mask the hydrophobicity of the lower half, an MspA mutant (MspA A96C) was 
obtained from the Niederweis group.  The alanine-cysteine switch does not affect the activity of 
the MspA, but it does provide a reactive group in the periplasmic loop of MspA.  This cysteine 
was used to attach a peptide (SRSRSRSRSRSGRSAGGGC) by a disulfide bond between the 
cysteine in the periplasmic loop and the cysteine in the peptide.  At 100% reaction, 8 peptides are 
added to the bottom of the MspA.  The peptide was designed to be very hydrophilic (containing 
mostly serine and asparagines residues) and also contains the consensus sequence for uPA 
(SGRSA).  Thus, when attached, the hydrophobicity of the lower half of the MspA is masked by 
the peptide.  The peptide can be cleaved off, though, leaving only a short, nearly neutral peptide 
(SAGGGC), drastically increasing the hydrophobicity of the lower half. 
To test the efficacy of the modified MspA, more cell tests were done.  MDA231 cells, 
which are known to express uPA,3 and Jurkat cells, which are known not to express uPA,4 were 
cultured separately in 12 well flat-bottom plates to 75% confluency.  Modified MspA (pro-
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MspA) was diluted to various concentrations in 1x PBS and added to the media.  The cells were 
placed in the incubator for 36 hours and then live cell counts were taken.   
 
Figure  3.3.6 WT, A96C and A96C non-uPA Toxicity 
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As can be seen in Figure  3.3.6, pro-MspA still retains a large degree of its toxicity against 
MDA231 (100% cell death at 100 nM), although it is slightly less.  This may be explained by the 
remnant peptide left on after cleavage may reduce the efficiency of insertion into the membrane.  
Pro-MspA does not show any toxicity against Jurkat cells up to 100 nM.  This would indicate 
that the peptide does prevent insertion and that insertion causes toxicity.  Without uPA to cleave 
off the peptide, pro-MspA is non-toxic.  Thus, pro-MspA can select for cells that are expressing 
uPA, and as a cancer associate protease, pro-MspA can select for cancer cells. 
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3.4. Conclusion 
The above study demonstrates that MspA shows strong potential as a replacement protein 
for the MAC in cancer therapy.  As discussed above, to demonstrate that MspA is a suitable 
MAC imitator three things must be proven: 1) MspA can poke holes in membranes; 2) the 
magnitude and multitude of these holes is enough to induce cell lysis or apoptosis; and 3) MspA 
can be modified somehow to select cancerous cells from non-cancerous cells.  Each of these was 
demonstrated above.  MspA pokes holes in artificial membranes that can be viewed with AFM or 
measured by current induction in electrochemical studies.  MspA is a very powerful toxin, 
showing toxicity in the nanomolar or subnanomolar range.  Finally, when modified with 
hydrophilic peptides, MspA can select which cells to kill based on protease production.   
As a MAC imitator, MspA could be a very potent anticancer treatment.  There is very 
little a cell can do to develop resistance to holes being poked in the membrane, so MspA could 
potentially be very effective even against multidrug resistance cancers.  Also, being targeted 
independently of the rate of dividing of the cells (being targeted to a cancer associated protease) 
could alleviate many of the well known side effects of cancer allowing higher systemic dosages 
and, perhaps more effective treatments.   
Many things still need to be considered, though.  MspA is a foreign protein and may 
induce a strong immune response that could either hamper or improve its effectiveness as a 
cancer therapy.  (The effectiveness would be hampered if the immune response removed the 
protein before it had a chance to act on the cancer.  The effectiveness could be improved if the 
immune response happened once the MspA was at the tumor site.  This could target the immune 
system to the cancer.)  General biological compatibility of the pro-MspA has not been tested 
either, nor has deliverability of the MspA to the tumor site.  To test all of these things, the next 
step would be to do in vivo tests of the MspA in a small animal model.   
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Appendix A NMR 
Figure   A.1 1H NMR Tert-butyl Cholesterol Acetate 
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Figure   A.2 13C NMR Tert-butyl Cholesterol Acetate 
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Figure   A.3 1H NMR Cholesterol Acetic Acid 
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Figure   A.4 13C NMR Cholesterol Acetic Acid 
 
 129 
Appendix B PRESSURE Resistance Calculations 
Figure   B.1 Bare Liposomes Fluorescent Intensity 
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Figure   B.2 Bare Liposomes Percent Release verses Osmotic Pressure Curve 
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Table   B.1 Bare Liposomes Fitting Constants 
A 11.0279 
B 10.8009 
C 236.3898 
D -0.0741 
E -2.6624 
R2 0.999998992 
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Figure   B.3 Sample 1 Fluorescent Intensity 
0
20000
40000
60000
80000
100000
120000
140000
470 490 510 530 550 570 590 610
Wavelength (nm)
In
te
ns
ity
 (a
rb
itr
ar
y 
un
its
)
0
0.25
0.5
1
1.5
2.5
5
 
 
Figure   B.4 Percent Release verses Osmotic Pressure Curve 
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Table   B.2 Fitting Constants 
A 10.8532 
B 10.7729 
C 236.3994 
D -0.1000 
E -0.4018 
R2 0.999999279 
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Figure   B.5 Sample 2 Fluorescent Intensity 
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Figure   B.6 Percent Release verses Osmotic Pressure Curve 
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Table   B.3 Fitting Constants 
A 10.9297 
B 10.7139 
C 236.3986 
D -0.0719 
E -0.5928 
R2 0.999999435 
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Figure   B.7 Sample 3 Fluorescent Intensity 
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Figure   B.8 Percent Release verses Osmotic Pressure Curve 
0.00%
20.00%
40.00%
60.00%
80.00%
100.00%
120.00%
0 10 20 30 40 50 60 70
Osmotic Pressure (atm)
%
 R
el
ea
se
 
 
Table   B.4 Fitting Constants 
A 10.9988 
B 10.6431 
C 236.3986 
D -0.0648 
E -0.5911 
R2 0.999999259 
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Figure   B.9 Sample 4 Fluorescent Intensity 
0
20000
40000
60000
80000
100000
120000
140000
470 490 510 530 550 570 590 610
Wavelength (nm)
In
te
ns
ity
 (a
rb
itr
ar
y 
un
its
)
0
0.25
0.5
1
1.5
2.5
5
 
 
Figure   B.10 Percent Release verses Osmotic Pressure Curve 
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Table   B.5 Fitting Constants 
A 10.9737 
B 10.6710 
C 236.3985 
D -0.0663 
E -0.6161 
R2 0.999999856 
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Figure   B.11 Sample 5 Fluorescent Intensity 
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Figure   B.12 Percent Release verses Osmotic Pressure Curve 
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Table   B.6 Fitting Constants 
A 11.0182 
B 10.6194 
C 236.3987 
D -0.0634 
E -0.5540 
R2 0.999998992 
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Figure   B.13 Sample 6 Fluorescent Intensity 
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Figure   B.14 Percent Release verses Osmotic Pressure Curve 
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Table   B.7 Fitting Constants 
A 10.9708 
B 10.7066 
C 236.3973 
D -0.0648 
E -0.8823 
R2 0.999999909 
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Appendix C Resistance Kinetics Calculations 
Figure   C.1 Bare Liposomes 15 Minutes 
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Figure   C.2 Percent Release verses Osmotic Pressure Curve 
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Table   C.1 Fitting Constants 
A 11.0155 
B 10.7478 
C 236.3928 
D -0.0566 
E -1.9564 
R2 0.99999666 
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Figure   C.3 Bare Liposomes 2 Hours 
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Figure   C.4 Percent Release verses Osmotic Pressure Curve 
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Table   C.2 Fitting Constants 
A 11.0250 
B 10.7513 
C 236.3923 
D -0.0715 
E -2.0768 
R2 0.99999666 
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Figure   C.5 Bare Liposomes 5 Hours 
0
500000
1000000
1500000
2000000
2500000
470 490 510 530 550 570 590 610
Wavelength (nm)
In
te
ns
ity
 (a
rb
itr
ar
y 
un
its
)
0
0.5
1
2
3
4
5
 
Figure   C.6 Percent Release verses Osmotic Pressure Curve 
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Table   C.3 Fitting Constants 
A 11.0545 
B 10.8115 
C 236.3881 
D -0.0727 
E -3.0599 
R2 0.999998869 
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Figure   C.7 Bare Liposomes 24 Hours 
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Figure   C.8 Percent Release verses Osmotic Pressure Curve 
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Table   C.4 Fitting Constants 
A 11.0451 
B 10.8126 
C 236.3885 
D -0.0691 
E -2.9678 
R2 0.999998799 
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Figure   C.9 Polymer Caged Liposomes 15 Minutes 
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Figure   C.10 Percent Release verses Osmotic Pressure Curve 
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Table   C.5 Fitting Constants 
A 8.2079 
B 8.0049 
C 236.3933 
D -0.0650 
E -1.1973 
R2 0.999999617 
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Figure   C.11 Polymer Caged Liposomes 2 Hours 
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Figure   C.12 Percent Release verses Osmotic Pressure Curve 
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Table   C.6 Fitting Constants 
A 10.8813 
B 10.7531 
C 236.4000 
D -0.0966 
E -0.2614 
R2 0.999997645 
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Figure   C.13 Polymer Caged Liposomes 5 Hours 
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Figure   C.14 Percent Release verses Osmotic Pressure Curve 
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Table   C.7 Fitting Constants 
A 11.0451 
B 10.8126 
C 236.3885 
D -0.0691 
E -2.9678 
R2 0.999998799 
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Figure   C.15 Polymer Caged Liposomes 24 Hours 
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Figure   C.16 Percent Release verses Osmotic Pressure Curve 
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Table   C.8 Fitting Constants 
A 10.8987 
B 10.7597 
C 236.4003 
D -0.1045 
E -0.1824 
R2 0.999995247 
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Appendix D Oleic Acid Effect Calculations 
Figure   D.1 3.7% Oleic Acid Bare Liposomes 
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Figure   D.2 Percent Release verses Osmotic Pressure Curve 
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Table   D.1 Fitting Constants 
A 10.9754 
B 10.8820 
C 236.3886 
D -0.0627 
E -2.9522 
R2 0.999997076 
 145 
Figure   D.3 2.5% Oleic Acid Bare Liposomes 
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Figure   D.4 Percent Release verses Osmotic Pressure Curve 
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Table   D.2 Fitting Constants 
A 11.0323 
B 10.7320 
C 236.3928 
D -0.0852 
E -1.9513 
R2 0.999997744 
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Figure   D.5 1.2% Oleic Acid Bare Liposomes 
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Figure   D.6 Percent Release verses Osmotic Pressure Curve 
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Table   D.3 Fitting Constants 
A 10.9677 
B 10.8020 
C 236.3927 
D -0.0933 
E -1.9888 
R2 0.999998044 
 147 
Figure   D.7 3.7% Oleic Acid Polymer Caged Liposomes 
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Figure   D.8 Percent Release verses Osmotic Pressure Curve 
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Table   D.4 Fitting Constants 
A 10.9487 
B 10.7659 
C 236.3953 
D -0.0860 
E -1.3751 
R2 0.999998045 
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Figure   D.9 2.5% Oleic Acid Polymer Caged Liposomes 
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Figure   D.10 Percent Release verses Osmotic Pressure Curve 
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Table   D.5 Fitting Constants 
A 2.0289 
B 1.9293 
C 235.9896 
D -0.1016 
E -3.2253 
R2 0.999991258 
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Figure   D.11 1.2% Oleic Acid Polymer Caged Liposomes 
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Figure   D.12 Percent Release verses Osmotic Pressure Curve 
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Table   D.6 Fitting Constants 
A 1.9076 
B 1.8484 
C 235.9912 
D -0.0993 
E -2.8404 
R2 0.999995579 
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Appendix E Cholesterol Effect Calculations 
Figure   E.1 20% Cholesterol – Bare Liposomes 
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Figure   E.2 Percent Release verses Osmotic Pressure Curve 
0.00%
20.00%
40.00%
60.00%
80.00%
100.00%
120.00%
0 10 20 30 40 50 60 70
Osmotic Pressure (atm)
%
 R
el
ea
se
 
Table   E.1 Fitting Constants 
A 11.1022 
B 10.7098 
C 236.3907 
D -0.0867 
E -2.4542 
R2 0.999995969 
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Figure   E.3 45% Cholesterol – Bare Liposomes 
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Figure   E.4 Percent Release verses Osmotic Pressure Curve 
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Table   E.2 Fitting Constants 
A 11.0612 
B 10.6192 
C 236.3969 
D -0.1010 
E -0.9850 
R2 0.99999815 
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Figure   E.5 20% Cholesterol – Polymer Caged Liposomes 
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Figure   E.6 Percent Release verses Osmotic Pressure Curve 
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Table   E.3 Fitting Constants 
A 10.8296 
B 10.8595 
C 236.3967 
D -0.0804 
E -1.0361 
R2 0.99999795 
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Figure   E.7 45% Cholesterol – Polymer Caged Liposomes 
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Figure   E.8 Percent Release verses Osmotic Pressure Curve 
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Table   E.4 Fitting Constants 
A 11.1366 
B 10.5138 
C 236.3981 
D -0.0554 
E -0.7073 
R2 0.999997088 
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Appendix F Revisiting Polymer Content and Crosslinking 
Figure   F.1 Bare Liposomes Fluorescence 
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Figure   F.2 Percent Release verses Osmotic Pressure Curve 
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Table   F.1 Fitting Constants 
A 13.4547 
B 12.8522 
C 236.3951 
D -0.0519 
E -1.4063 
R2 0.999999068 
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Figure   F.3 0.6% Polymer 50% Crosslinking Fluorescence 
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Figure   F.4 Percent Release verses Osmotic Pressure Curve 
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Table   F.2 Fitting Constants 
A 13.5202 
B 12.7588 
C 236.3965 
D -0.0349 
E -1.0863 
R2 0.999998988 
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Figure   F.5 0.6% Polymer 75% Crosslinking 
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Figure   F.6 Percent Release verses Osmotic Pressure Curve 
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Table   F.3 Fitting Constants 
A 13.3590 
B 12.9129 
C 236.3973 
D -0.0495 
E -0.8853 
R2 0.999999211 
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Figure   F.7 0.6% Polymer 100% Crosslinking 
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igure   F.8 Percent Release verses Osmotic Pressure Curve 
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Table   F.4 Fitting Constants 
A 13.4649 
B 12.8154 
C 236.3966 
D -0.0387 
E -1.0627 
R2 0.99999877 
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Figure   F.9 1.3% Polymer 50% Crosslinking 
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Figure   F.10 Percent Release verses Osmotic Pressure Curve 
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Table   F.5 Fitting Constants 
A 13.4523 
B 12.8394 
C 236.3960 
D -0.0385 
E -1.2011 
R2 0.999998748 
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Figure   F.11 1.3% Polymer 75% Crosslinking 
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Figure   F.12 Percent Release verses Osmotic Pressure Curve 
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Table   F.6 Fitting Constants 
A 13.5403 
B 12.7184 
C 236.3976 
D -0.0369 
E -0.8366 
R2 0.999996771 
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Figure   F.13 1.3% Polymer 100% Crosslinking 
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Figure   F.14 Percent Release verses Osmotic Pressure Curve 
0.00%
20.00%
40.00%
60.00%
80.00%
100.00%
120.00%
0 10 20 30 40 50 60 70 80 90 100
Osmotic Pressure (atm)
%
 R
el
ea
se
 
 
Table   F.7 Fitting Constants 
A 16.5264 
B 15.4923 
C 236.3980 
D -0.0354 
E -0.7421 
R2 0.999998231 
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Figure   F.15 5.3% Polymer 50% Crosslinking 
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Figure   F.16 Percent Release verses Osmotic Pressure Curve 
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Table   F.8 Fitting Constants 
A 16.3310 
B 15.7604 
C 236.3944 
D -0.0486 
E -1.5848 
R2 0.999998514 
 162 
Figure   F.17 5.3% Polymer 75% Crosslinking 
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Figure   F.18 Percent Release verses Osmotic Pressure Curve 
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Table   F.9 Fitting Constants 
A 15.4834 
B 16.6370 
C 236.3935 
D -0.0562 
E -1.8014 
R2 0.99999774 
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Figure   F.19 5.3% Polymer 100% Crosslinking 
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Figure   F.20 Percent Release verses Osmotic Pressure Curve 
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Table   F.10 Fitting Constants 
A 15.8163 
B 16.2978 
C 236.3940 
D -0.0579 
E -1.6845 
R2 0.999999097 
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Appendix G Protease Sensitivity First Test 
Figure   G.1 No uPA Fluorescent Intensity 
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Figure   G.2 + uPA Fluorescent Intensity 
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Appendix H Protease Sensitivity Second Test 
 
Figure   H.1 Baseline Fluorescent Intensity 
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Figure   H.2 – uPA Fluorescent Intensity 
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Figure   H.3 + uPA Fluorescent Intensity 
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Appendix I Statistical Calculations 
All statistics in this dissertation were done using a student’s t-test to determine how likely 
the two samples being compared are the same.  Equal variances were not assumed.  The 
calculations used are as follows: 
 
1
x x
n





 
where  is standard deviation, x is the measured value, xbar is the mean of the sample,  
and n is the number of measurements. 
The t value is calculated as follows: 
1 2
1 2
x x
x xt
s


  
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x xs n n
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   
where t is the t value.  The degrees of freedom (D.F.) can also be calculated by: 
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The t value and the degrees of freedom can then be used to calculate the p value by 
plugging into a p value calculator.  P values less than 0.05 are generally thought of as significant, 
and P values less than 0.01 are considered very significant.  Significance increases with 
decreasing P value after this. 
 
